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ABSTRACT 
 
 
 Sensitive and quantitative detection of proteomic biomarker panels is expected to 
significantly improve early diagnosis and therapy monitoring for cancers and other 
diseases. We developed a novel in-vitro diagnostics approach to multiplexed biomarker 
detection based on molecular recognition mediated nanoparticle self-assembly. The 
nanoparticles self-assemble into agglomerates via a rapid, single step, fluid phase reaction. 
The individual nanoparticles and agglomerates can be discriminated based on their light 
scattering properties and by other analytical techniques. 
 Cadmium selenide quantum dots conjugated to polyclonal antibodies self-
assemble to form quantum dot agglomerates in the presence of antigens, including 
angiopoietin-2, vascular endothelial growth factor A, and human immunoglobulin G. The 
reaction mixtures were characterized by one or more analytical techniques including 
dynamic light scattering, electrical sensing zone method (Coulter counter), and flow 
cytometry to characterize and quantify the self-assembled agglomerates. The size 
distribution of the quantum dot agglomerates was estimated to be between 500 nm and 
4 microns. The individual components of the agglomerates are significantly smaller. 
Measured by dynamic light scattering, the quantum dot-antibody conjugates have a 
hydrodynamic diameter of 45 nm, while the antigens are 5 to 10 nm in diameter. 
 We demonstrated quantitative and sensitive detection using flow cytometry of 
the candidate cancer biomarkers vascular endothelial growth factor A and angiopoietin-2. 
Non-multiplexed detection of the antigens was demonstrated with 50 femtomolar 
sensitivity limit. Multiplexed detection, using two quantum dot populations with distinct 
 ii 
emission spectra of vascular endothelial growth factor A and angiopoietin-2 was 
demonstrated in the physiologically relevant picomolar concentration range.  
 The kinetics of the self-assembly process were examined by measurements of the 
angiopoietin-2 mediated self-assembly of quantum dots over time, revealing a sigmoidal 
process. Antigen concentration modulates the slopes and inflection times of the sigmoidal 
kinetics curves. 
 Further refinements to improve the sensitivity and specificity of this novel 
proteomic biomarker detection technique may improve the screening, diagnostics, and 
therapy response monitoring for cancers and other diseases. This approach to studying 
nanoparticle self-assembly may also provide a valuable tool for understanding the 
fundamental characteristics of nanoscale particle agglomeration. 
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CHAPTER 1 
 
INTRODUCTION 
 
Rationale 
 The rapidly growing fields of genomics and proteomics are giving rise to a 
fundamentally molecular understanding of diseases. Genetic mutations translated to the 
proteome and the consequent abnormal protein function and altered intercellular 
signaling are at the root of many diseases. The discovery of the proteomic abnormalities 
underlying various pathologies is poised to lead to a revolution in medicine. The new 
proteome based understanding of diseases will provide new targets for therapy, as well 
as increase the use of protein detection technologies towards diagnosis, monitoring and 
management of many diseases in a highly effective and personalized manner. Antibody 
based detection technologies are prime candidates for this application, due to the proven 
and traditional use of the highly specific and well understood antibody-antigen 
interaction. 
 Cancers are a group of pathologies that constitutes one of the leading causes of 
mortality in the developed world. Moreover, the major factors leading to mortality in 
cancers are delayed detection, metastasis, and lack of data about the efficacy of therapy, 
hindering countermeasures to acquired drug resistance and relapse of the disease[1, 2]. 
Hence, discovery of cancer marker proteins is one of the leading goals of proteomics 
research. The diagnosis and treatment of other significant diseases, including heart 
disease and Alzheimer's disease, is also expected to benefit from proteomic approaches. 
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Many marker proteins that correlate with the presence and behavior of cancers have 
been identified [3-12], and more significant discoveries are expected. The predictive 
power of these marker proteins, as well as the significant increase in predictive power 
from examining a panel of molecules has also been recognized [13-16]. Hence, there is a 
strong motivation for detecting these proteins at very low concentration, enabling 
routine and frequent monitoring and successful management of the disease[14, 15, 17]. 
 In research settings, proteomic profiling of cancers is carried out by analyzing 
proteins in sera and tissues from diseased subjects by mass spectrometry, ELISA assays, 
2D-PAGE etc. However, a clinically suitable detection method for assessing a few 
specific molecules from the numerous present in a biological sample is, at present, a 
challenge. While they are suitable in research settings, the conventional protein detection 
methods are unsuitable for molecular profiling in clinical settings, falling short on one or 
more of the important parameters of speed, sensitivity, multiplexing capability, 
production of quantitative data, ease of implementation and cost.  
 The unique properties of nanoparticles and nanoparticle-biomolecule conjugates 
can provide novel ways of achieving these objectives. Our proposed approach – 
detection of micro-agglomerates formed by specific self assembly of nanostructures – 
offers a potent way to tackle this problem. Detection of pathogens by molecular 
recognition-based self-assembly was proposed as far back as 1956 in the form of the 
latex agglutination test[18], which is still used for detecting bacteria[19-21], and for 
determining blood types, but is unsuitable for sensitive detection of low concentration 
small molecules. Nanoparticle based variants of the agglutination test have been 
demonstrated for small molecules such as DNA fragments[22] and proteins[23]. In both 
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these demonstrations, the change in plasmon resonance due to self assembly of the 
metal nanostructures was spectroscopically monitored. Small molecules have also been 
detected using quantum dots using antibody mediated coincidence of multiple quantum 
dots with different emission wavelengths[24, 25]. 
 Based on this evidence, I propose to develop a simple and robust method for 
quantitative multiplexed proteomic antigen detection using antibody-antigen molecular 
recognition mediated quantum dot self assembly. 
 
Specific Aims 
 I propose to develop this proteomic diagnostic method over the course of three 
specific aims: 
 
Aim 1 – Investigate quantitative correlation between antigen concentration and 
nanoparticle self-assembly. 
 I propose to develop and optimize the protocols for quantum dot-antibody 
conjugation for antigen detection, incubation of antigens with the biofunctionalized 
quantum dots, and characterization of the nanoparticle agglomerates with various 
analytical methods. I will characterize the biofunctionalized nanoparticles and 
nanoparticle agglomerates by dynamic light scattering, electrical sensing zone method, 
and flow cytometry. Based on the results of these characterizations, a method for 
investigating quantitative correlation between the antigen concentration and nanoparticle 
agglomerates will be selected. This correlation will be investigated for at least two 
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proteomic antigens, and the feasibility of using this technique for quantitative biomarker 
detection will be determined. 
 
Aim II – Develop the protocol for multiplexed detection of two distinct proteomic 
biomarkers. 
 I propose to develop a protocol for quantitatively detecting two different antigens 
from a single multi-antigen solution. Two quantum dot populations with distinct 
fluorescence characteristics will be used for detecting one biomarker each. I will 
characterize the cross-reactivity between the biofunctionalized quantum dots and non-
specific antigens at multiple concentrations, as well as the effect of using multiple 
quantum dot populations on the agglomerate characterization abilities of the analytical 
instrument and method. The reaction and analytical protocols will be modified to 
minimize the effect of these parameters on the antigen detection capabilities and the 
sensitivity limit will be optimized to enable multiplexed detection at physiologically 
relevant biomarker concentrations. 
 
Aim III – Characterize the kinetics of molecular recognition mediated nanoparticle self-
assembly. 
 The kinetics of nanoparticle agglomeration may provide important information 
about the agglomeration mechanism, as well as about optimizing the reaction and 
characterization protocol to enable rapid and sensitive detection. The kinetics of 
agglomeration mediated by specific and non-specific molecular recognition are expected 
to be significantly different, based on theoretical understanding of the process, as well as 
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literature evidence from similar techniques. I will quantify the kinetics of nanoparticle 
agglomeration for a range of physiologically relevant concentration values of a candidate 
cancer biomarker. The kinetics may suggest the feasibility of alternative system 
parameters that may be used for quantitatively detecting biomarkers, as well as the 
optimal protocols for minimizing the effect of non-specific intermolecular interactions on 
the sensitivity and specificity of biomarker detection. 
 
Background 
 Intermolecular interactions - dipole-dipole, hydrogen bonding and electrostatic - 
are important physical phenomena. These interactions, which generate important effects 
such as the hydrophobic/hydrophilic forces, contribute to spontaneous and stable 
organization of simple molecules into interesting structures like the lipid monolayers, 
bilayers and vesicles that are of particular importance in biological systems. Biological 
evolution has further generated sophisticated molecules capable of taking advantage of 
such intermolecular forces and forming highly specific and functional multi-molecular 
structures, in effect leading to intermolecular recognition. One of the important 
recognition interactions is the antibody-antigen interaction that forms 
immunocomplexes. Along with being an extremely important biological process, the 
antibody-antigen interaction is useful as a core component of technologies used for 
diagnosing numerous pathologies by detecting and quantifying the corresponding 
antigens. 
 Molecular recognition, an important mechanism in biological systems, also 
provides a powerful tool for materials science, by directing the self assembly of nanoscale 
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molecules and particles into larger structures. Typically, these self assembled structures 
are significantly larger than their individual components, and hence can be detected easily 
by optical investigation, providing a simple and effective way to detect small molecules. In 
fact, agglomeration of micro particles into larger assemblies – specifically, latex 
agglutination - has been used since 1956 as a way of detecting pathogens. The unique 
optical properties of nanoparticles, such as fluorescence and plasmon resonance, offer 
the possibility of further increasing the sensitivity of aggregation based detection. We 
propose a technology involving molecular recognition mediated self assembly of 
fluorescent semiconductor nanoparticles (quantum dots). The resulting self assembled 
structures will be characterized, providing novel way to detect low concentrations of 
known antigens. This technique works completely in the fluid phase and has the potential 
for better sensitivity, quantification, multiplexing and ease of use than current detection 
methods. 
 
Critical Requirements for a Clinically Applicable Proteomic Profiling Technique: 
 The goals of clinical proteomics are: a) early detection and diagnosis of diseases, 
b) determination of disease subtype and status to guide personalized therapy, and c) 
frequent monitoring of disease progress for checking effectiveness of the therapy. To 
fulfill these objectives, there are several attributes required of any proteomic profiling 
technology: 
1) High sensitivity and dynamic range: While some disease states may involve 
uniquely expressed proteins, the difference between the proteome of diseased and 
normal states is often only in the different expression levels of the same proteins. 
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Furthermore, the amount of disease specific proteins in any diagnostic sample will likely 
be below the amount of abundant proteins by many orders of magnitude. This is 
especially true for early detection of diseases. In early stages of a disease, the amount of 
affected tissue is typically small, and consequently, the marker proteins are being 
presented in diminished quantities, especially in peripheral fluids. Hence, for successful 
detection, the profiling technology must be sensitive to extremely low concentration of 
proteins, while having a sufficient dynamic range of measurement. 
2) Appropriate multiplexing capabilities: Many disease states will be best diagnosed 
and classified based on the expression levels of a panel of proteins, reflecting the 
complex multifaceted molecular basis of the diseases. Since successful early detection 
of diseases will likely involve routine screening for multiple diseases, multiplexing 
abilities will be required for detection of multiple panels of proteins – perhaps on the 
order of hundreds of proteins. 
3)  Minimally invasive, low sample volume: A routine and/or frequent diagnostic 
should be minimally invasive and require minimal total sample volume for successful 
detection. A serum based diagnostic requiring low blood volume will be ideal. 
4) Rapid, easy to administer and cost effective: The most popular and effective 
diagnostics produce results quickly, do not require highly trained technical personnel, 
and cost very little per administration. 
 
Molecular Profiling Methods 
 The most prominent of the numerous techniques for molecular profiling, from 
either clinical or research perspective, are discussed below, with respect to their 
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performance on the above mentioned attributes. Profiling methods that are currently 
used in clinical or research settings, as well as those that are currently being developed to 
take advantage of novel nanoscale phenomena are discussed. 
 Enzyme linked immunosorbent assay (ELISA) is possibly the most popular protein 
detection technique, employed widely in clinical settings as well as in molecular profiling 
research. The popularity of ELISA is partly because of its simplicity and cost effectiveness. 
Typically, the target antigen is captured by an antibody adsorbed on the polymer surface 
of the well plate. A second antibody, coupled to an enzyme is then added to the wells, 
followed by a chemiluminescent substrate for the enzyme. The presence and intensity of 
the luminescence is measured and provides a measure of the antigen. While ELISA is a 
simple and useful technique, it is also highly labor and time intensive, and typically 
requires on the order of 105 copies of the antigen for successful detection. 
 Polymerase chain reaction (PCR) is another widely used technique, although one 
that is usually applied to polynucleotide rather than protein detection. The target 
molecule is copied by cycling of the mixture of original sample, primers, excess 
nucleotides, and polymerase enzymes over a defined thermal program. PCR is 
remarkable for its sensitivity, with reports of successful detection of poly-nucleotides 
from sample containing only one copy/ml[26], although routine detection requires on the 
order of 101 -102 copies. One the other hand, any contaminant polynucleotide 
recognized by the same primers is also amplified, resulting in increased background.  
 Immuno-PCR , a hybrid of the above two techniques, utilizes PCR amplification of 
polynucleotide sequences associated with specific antibody-antigen complexes, resulting 
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in PCR-like sensitivity for protein detection[27, 28]. A nanoparticle based variant of this 
technique has also been developed recently[29]. 
 All three of these techniques are generally considered unsuitable for high 
throughput assays and/or simultaneous detection multiple proteins as they are time 
intensive, and not inherently amenable to multiplexed detection. 
 Mass spectrometry (MS) is amenable to multi-protein detection, and is one of the 
techniques used for proteomic analysis of serum or tissue samples, mainly for discovery 
of disease biomarkers. MS generates information about the number of proteins in a 
sample, and the charge to molecular weight ratio of these proteins. Since these quantities 
are dependant mainly on the protein content of the sample, and are easy to compare 
across samples, MS is an excellent tool for recognizing protein expression patterns 
indicative of cancers[17, 30-32]. However, MS suffers from several drawbacks. Critically 
for early diagnosis applications, detection of low concentration proteins in the presence 
of abundant proteins by MS is difficult to achieve. MS and also requires expensive 
instrumentation and expertise, and is thus an unlikely choice for a clinical proteome 
profiling technique. 
 Gel electrophoresis (GE) is another technique that was widely used in early 
proteomics research, especially as two dimensional polyacrylamide gel electrophoresis 
(2D PAGE)[33, 34]. 2D PAGE has the highest resolving power of any protein separation 
technique – being able to separate up to 104 proteins[35]. The separated proteins can be 
analyzed with various analysis techniques including MS, antibody based detection similar 
to Western blot, and more. Despite its advantages, GE is not suitable for clinical 
proteomic profiling applications; especially since sensitivity of 2D PAGE is about 106 
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copies, and even then, the low concentration proteins are often go undetected in the 
presence of high concentration proteins. Furthermore, predominantly hydrophobic 
proteins, such as membrane proteins are often resolved poorly, and gel to gel 
replicability remains a problem. In addition, GE is also very labor and time intensive. 
 Antibody Microarrays, similar to DNA microarrays, and are also used for 
detecting numerous proteins simultaneously, often directly from biological fluids. In an 
antibody microarray, antibodies to 104 to 106 different proteins can be immobilized in an 
array of spots on a solid surface, with each spot containing a unique antibody. The 
captured antigens are detected by fluorescence measurements. Antibody microarrays, 
apart from being prone to several shortcomings of the antibody-antigen interaction based 
techniques, are also unsuitable for clinical profiling due to some inherent properties of 
the array based technique. Maximum sensitivity in an array technique would be achieved 
when each antigen interacts with all possible antibodies. Unfortunately, due to the 
diffusion limited interaction, and the large number of spots, this is not achievable in a 
practical amount of time[36]. 
 Along with the technique specific limitations of the above multi-protein detection 
methods, they all have a common flaw that render them sub-optimal for diagnostic 
proteomic applications. These strategies are all suitable for detection of 103 or more 
proteins. For detecting a particular disease, or a set of diseases, it is unlikely that such 
large detection capabilities will be required. 
 The conventional single or multi protein detection methods mentioned above are 
a part of the biological and clinical toolkit. However, quite a few novel molecule 
detection methods are being developed to take advantage of the growing understanding 
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of nanoscale physical phenomena[37-39]. Some of the nano based methods that are 
promising for proteomic profiling applications are discussed below. 
 Nanocantilever Sensors involve lithographically manufactured arrays of 
cantilevers. Biomolecular interactions are detected by monitoring the mechanical 
properties of the detection device[40-44]. Antibodies can be bound to the cantilever 
surfaces, and upon antigen binding, the natural resonance frequency of the cantilever 
frequency of the cantilevers changes due to change in mass as well as change in elasticity 
of the composite structure[45, 46]. Currently, the sensitivity of these cantilever arrays - 
at the level of picograms/ml - is not the strongest advantage of the technique, but being 
based on lithographic technology, the cantilever arrays are promising due to their 
customizability, ease of production and cost of manufacturing. 
 Nanowire and Nanotube Sensors take advantage of the sensitivity of the 
conductive properties of the nanowires to the nearby environment. The conductivity of 
the nanostructures is monitored and a change in conductivity is indicative of a binding 
event[47-50]. Nanowire sensors usually require a combination of the bottom-up and 
top-down fabrication methods. While this technique is at the early stages of 
development, and many problems are yet to be solved, the fundamental principle makes 
it very attractive for the purpose of detecting multiple low concentration species 
rapidly[51]. 
 Nanoparticle based methods that take advantage of unique electro-optical, 
chemical and structural properties of nanoparticle-biomolecule composites to detect the 
presence of the target analyte are also being actively researched[52-56]. Such systems 
take advantage of phenomena such as fluorescence resonance energy transfer (FRET)[57, 
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58], localized surface plasmon resonance (LSPR)[59-63], surface enhanced Raman 
scattering (SERS)[64-66]. While quantum dots are ideal candidates for FRET based 
sensors, metal nanoparticles are being investigated for LSPR and SERS based sensors. 
SERS especially is being investigated as an analysis technique for other protein binding or 
separation techniques such as ELISA and GE. 
 Nanoparticle Self Assembly based methods are a subset of the nanoparticle based 
methods that depend on formation of structures of various complexity and sizes from 
nanoparticle biomolecule conjugates in the presence of the target molecules. The 
colorimetric change in metal nanoparticle solution based on inter-nanoparticle distance 
has been long recognized[67]. The colorimetric monitoring of interactions between 
biomolecule-nanoparticle conjugates has also been carried out[68] and this phenomenon 
has been exploited for the detection of simple molecules like glucose[69], 
polynucleotides[70], and proteins[23]. Detection of target molecules based on 
coincidence of two different colored quantum dots has also been demonstrated[24, 25]. 
 
Core Components of the Proposed Technology 
 The fundamental phenomena related to the proposed technology are well 
understood. Quantum dots have been thoroughly investigated with regards to synthesis 
and fluorescence properties [71-77], surface modification for biological applications - 
including conjugation with proteins and antibodies [78-84] and multiplexed biological 
applications [85-88]. From this literature evidence, it is apparent that quantum dots are 
suitable for the proposed ex-vivo diagnostic technology[89]. 
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 Antibody-antigen interactions mediated self assembly is well established in the 
form of the agglutination test[18, 19] and nanoparticle self assembly based detection of 
proteins has also been demonstrated recently [23, 90, 91].  
 While the self assembled micro-structures can be detected via dynamic laser 
scattering (DLS) of the bulk solution, as well as by electro-resistive particle counting such 
as Coulter Counter, using a flow cytometer or similar instrument provides a much more 
powerful way of acquiring and analyzing the data. In a flow based setting, the small 
volumes of the sample can be analyzed – leading to improved sensitivity. Furthermore, 
flow cytometric analysis allows for simultaneous measurement of various properties of 
the particles such as forward scatter, side scatter, and the fluorescence intensity at 
multiple wavelengths, enabling sophisticated multiplexed detection. Flow cytometry is an 
established technology and the instrumentation is widely available in clinical settings. This 
can prove beneficial for clinical acceptance of the proposed technique. 
 
Advantages of the Proposed Technology 
 Although of the proposed technology is currently in early stages of investigation, 
the basic capabilities, as predicted from the fundamental theoretical considerations and 
demonstrated by preliminary evidence, appear to be suitable for multiplexed proteomic 
profiling applications. These fundamental features are: 
1) Multiplexing capabilities: Due to the tunable emission spectra of quantum dots, 
multiple colors can be detected simultaneously and from a single sample. If each 
antigen is detected by a single colored population of quantum dots, this enables 
simultaneous detection of multiple proteins. While the number different emission 
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wavelengths of the quantum dots currently commercially available is less than ten, this 
number can increase significantly by using quantum dots of different semiconducting 
materials [85, 92]. 
2) Sensitivity and Dynamic Range: The very high quantum efficiency and high 
fluorescence intensity of quantum dots is well known. Coupled with a sensitive 
detection technology such as photomultiplier tubes (PMT) or charge coupled diodes 
(CCD), an extremely low concentration of quantum dots can be detected. Since the 
proposed self assembly is a two component reaction, the dynamic range can be varied 
depending on the possible concentration range of the target antigen. 
3) Minimally Invasive: The proposed diagnostic is ex-vivo and completely in the fluid 
phase, and hence can be carried out easily in serum, lymph or other suitable fluid 
samples. 
4) Low sample volume: Due to the high sensitivity, and since the actual detection of 
agglomerates can be carried out in few microliters of the sample, a milliliter sample will 
likely be sufficient even for acquiring a statistically significant signal, as well as screening 
for multiple diseases, depending on the concentration of the target analyte. 
5) Rapid results: The agglomeration reaction in a well dispersed solution proceeds 
very rapidly – in under an hour. The actual measurement is also fast, and results will 
likely be obtained in under a couple of hours 
6) Cost effective: Quantum dots, one of the essential analytes needed for the 
diagnostic can be synthesized easily and cheaply. Antibodies are already a standard 
diagnostic product. Since very low quantities of these reagents will be needed, the 
diagnostic will be cost effective. Also, during development, the characterization is being 
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carried out on flow cytometers. However, standard FACS instrumentation is not a 
necessity. A simpler and cheaper dedicated instrument based on micro-fluidics and 
semiconductor optics can be envisioned for clinical application. 
7) Easy to administer: In a dedicated instrument, the sample preparation and analysis 
from extracted fluid could be completely automated. Even in a cytometers based 
analysis, the initial sample preparation can be automated, and the analysis can be 
carried out using high throughput screening attachments, making the diagnostic 
administrable by a minimally trained operative. 
 
Other Possible Applications 
 Since this technique is based on antibody antigen interaction, it can presumably be 
used to detect any analyte for which suitable molecular recognition molecules can be 
identified. Apart from being a general clinical diagnostics technique, applications in bio-
defense and environmental monitoring are feasible for target analytes that can be 
suspended or dissolved in an aqueous buffer. This approach to studying nanoparticle self-
assembly may also provide a valuable tool for understanding the fundamental 
characteristics of nanoscale particle agglomeration. 
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CHAPTER II 
 
QUANTUM DOT SELF-ASSEMBLY FOR PROTEIN DETECTION 
WITH SUB-PICOMOLAR SENSITIVITY 
 
Summary 
 A novel approach to sensitive and rapid antigen detection is described. In the 
presence of a specific antigen, quantum dot-antibody conjugates rapidly self-assemble 
into agglomerates that are typically more than one order of magnitude larger than their 
individual components. The size distribution of the agglomerated colloids depends on, 
among other things, the relative concentration of quantum dot conjugates and antigen 
molecules. Quantum dot agglomerates mediated by antigen recognition were 
characterized by measuring their light scattering and fluorescence characteristics in an 
unmodified flow cytometer. Protein antigens angiopoietin-2 and mouse IgG were 
detected to sub picomolar concentrations using this method. This simple technique 
enables the potential simultaneous detection of multiple antigenic biomarkers directly 
from physiological media and could be used for early detection and frequent screening of 
cancers and other diseases. 
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 Figure 1. Schematic depiction of antigen detection by molecular interaction mediated 
self assembly. Multivalent interactions between molecular recognition elements such as 
antibody-antigen, complementary polynucleotide sequences, or aptamer-target could 
provide a simple technique for analyte detection. The capture molecules for different 
analytes can be conjugated with quantum dots with different fluorescence emission 
characteristics to enable multiplexed detection such as for biomarker panels. The analyte 
molecules mediate directed self-assembly of the quantum dot conjugates. The size 
distribution of these conjugates is proportional to the amount of analyte molecules 
present when other factors affecting self-assembly such as QD concentration and 
incubation period are constant. With techniques such as flow cytometry, a sophisticated 
and quantitative characterization of the colloidal solution is carried out, providing a 
simple, rapid and powerful technique for accurate quantification of analytes. Figure not to 
scale. 
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Introduction 
 The growing proteomic understanding of disease processes can be a powerful 
tool for diagnosing, prognosing and monitoring cancers and other medical conditions. An 
assay that detects multiple specific molecules from the complex mixture present in 
serum, and is rapid, sensitive and simple to administer, would be ideal for such an 
application. At present this is a practical, clinical challenge. Antibody-based recognition 
remains one of the most promising strategies for such applications but conventional 
approaches such as parallelized enzyme linked immunosorbent assay (ELISA), gel 
electrophoresis, and protein microarrays are suboptimal for point-of-care molecular 
profiling on the basis of cost, complexity, and speed. 
 Detection of pathogens by molecular recognition-based self-assembly of 
microspheres was proposed as far back as 1956 in the form of the semi-quantitative latex 
agglutination test[1], which is still used for detecting bacteria[2-4]. Nanoparticle-based 
agglutination tests utilizing surface plasmon resonance (SPR) shift have been recently 
demonstrated for the detection of DNA fragments[5] and proteins[6]. Biomolecules have 
also been detected using fluorescent semiconductor nanoparticles (quantum dots) by 
either spatial[7] or temporal[8] coincidence of multicolored quantum dot-antibody 
conjugates. Flow cytometric microsphere-based immunoassay (FMBA) has been 
proposed for the simultaneous detection of multiple proteins[9, 10]. FMBA assays are 
essentially antigen capture sandwich immunoassays on microspheres, and use 
microsphere size and/or fluorescence intensity as discriminating characteristics for 
multiplexing. Compared to these techniques, antigen mediated quantum dot 
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agglomeration combined with flow based detection on a microfluidic device, has the 
potential to offer better sensitivity, ease of use, speed, and cost of testing. 
 We demonstrate here this novel method for sensitive, simple, and rapid fluid 
phase detection of proteins based on simultaneous measurement of multiple properties 
of the colloidal mixture. Quantum dots (QDs) are conjugated with polyclonal antibodies 
(Ab) using a streptavidin-biotin interaction[11-13]. In the presence of the appropriate 
antigen molecules, these QD-Ab conjugates rapidly self-assemble into colloidal structures 
with sizes that are one to two orders of magnitude larger than the constituents (Figure 
1). The size, structure and fluorescence characteristics of these self assembled structures 
are a function of the relative concentrations of the QD-Ab conjugates and the antigen 
molecules, among other factors. These attributes of the colloidal structures can be 
characterized by several techniques, including flow cytometry, dynamic light scattering, 
and electrical sensing zone or Coulter counter method. Flow cytometry is a powerful 
technique routinely used in biomedical laboratories for rapidly assessing multiple 
characteristics of a large population of cells and other microparticulates suspended in a 
hydrodynamically focused fluid stream[14]. The use of flow cytometers is common in 
clinical medicine, and the protein detection strategy described here could be adopted 
into clinical practice relatively easily. The basic principle of flow cytometric analysis can 
also be implemented on a microfluidic chip[15, 16], implying the ability to create a 
compact point-of-care diagnostic or field deployable analyte detection instrument. 
Conventional materials chemistry methods such as SPR shift assays measure the average 
spectral properties of the whole sample. By contrast, flow cytometry enables 
interrogation of virtually every individual particle in the sample and simultaneously 
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measures multiple characteristics such as forward light scatter, side light scatter, and 
fluorescence intensity at multiple wavelengths. This enables a sophisticated discrimination 
between individual events and detailed multiparametric mapping of the whole 
population. The detection of extremely rare events is thus possible, enabling detection of 
molecular analytes with high sensitivity and resolution. Furthermore, since flow 
cytometry is capable of detecting multiple flurophores, simultaneous QD based detection 
of multiple analytes could be achieved using different QD populations targeted for 
detection of different antigens. 
 The self assembled quantum dot structures generated in this study were detected 
based on their fluorescence intensity. The forward light scatter, side light scatter, and 
fluorescence emission at multiple wavelengths was recorded for each particle detected. 
The fraction of all events above a size threshold corresponding to 0.5 μm latex size 
standard spheres was proportional to the antigen concentration.  One antigen used in 
these experiments was human angiopoietin-2 (ang-2), a 66kDa protein involved in neo-
angiogenesis[17, 18]. Due to the importance of neo-angiogenesis in the proliferation of 
various cancers, ang-2 is a protein of interest as cancer marker and therapy target[19, 
20] and has also been shown to correlate with the invasiveness and growth of various 
cancers[17, 21-23]. Detection of mouse IgG (mus) is also demonstrated using the same 
method. 
 The antigens in this study were detected to sub-picomolar concentration, 
comparable to the detection of the same molecules by conventional techniques such as 
ELISA or Western blot. Thus, the agglomeration based detection strategy is already 
comparable to conventional immunorecognition techniques in terms of sensitivity. The 
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flow based detection approach also enables characterization of multiple properties of 
individual self assembled structures, thus providing a tool for investigating self-assembly in 
a novel and powerful manner, which may lead to insights into this important nanoscale 
phenomenon. 
 
Experimental 
 
Materials 
 Streptavidin-coated quantum dots with 705 nm (#Q10161MP), 585 nm 
(#Q10111MP), and 525 nm (#Q10141MP) emission wavelengths were purchased from 
Invitrogen (Carlsbad, CA) and used as received for flow cytometry, bulk agglomeration 
fluorescence and dynamic light scattering experiments respectively. Biotin conjugated 
anti-angiopoietin-2 polyclonal antibody (anti-ang-2) (#BAF623 ) and recombinant human 
angiopoietin-2 (ang-2) (#623-AN-025 ) were purchased from R&D Systems 
(Minneapolis, MN), reconstituted in Tris-buffered saline (TBS) containing 0.1% bovine 
serum albumin (BSA). Mouse IgG (mus) (#23873), human IgG (hum) (#23872) and 
rabbit IgG (rab) (#23874) were purchased from Polysciences Inc (Warrington, PA), and 
reconstituted in 1x phosphate buffered saline (PBS). All reconstituted samples were 
aliquoted and stored at - 20ºC. The aliquots were thawed and diluted to appropriate 
concentration using the PBS with 0.1% BSA (PBS-BSA) immediately prior to use. Biotin 
conjugated goat-anti-mouse IgG (GaM) (#553999) was purchased from BD Biosciences 
(San Jose, CA) and stored at 4ºC. All other chemicals used were ACS reagent grade. 
10mM borate buffer was used for Zetasizer and bulk fluorescence measurement 
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experiments. Buffers were prepared in deionized water, and filtered through a 0.2 μm 
filter prior to use. 
 Flow cytometric measurements were carried out on Beckton Dickinson (BD) 
FACSCalibur. BD FACSAria and BD LSR II flow cytometers were also used for 
optimizing detection parameters. Bulk fluorescence was measured in BioTek (Winooski, 
VT) Synergy HT multi-detection microplate reader. Dynamic light scatter (DLS) 
measurements were carried out on a Malvern Instruments (Malvern, UK) Zetasizer 
Nano ZS. Fluorescence measurements were carried out in a Nanodrop Technologies 
(Wilmington, DE) ND-3300 fluorospectrometer. 
 
Quantum dot-antibody conjugation  
 The quantum dot-streptavidin conjugates (QD) and biotinylated anti-angiopoietin-
2 polyclonal antibody (anti-ang-2) or biotinylated goat-anti-mouse polyclonal antibody 
(GaM) were mixed in PBS-BSA at QD:antibody molar ratio of 1:3 and 1nM QD 
concentration. The conjugation was monitored by particle size estimation in the reaction 
mixture by DLS. The conjugate was diluted to appropriate concentrations and used 
immediately after synthesis. 
 
Antigen Induced Self Assembly  
 The QD-antibody (QD-Ab) conjugate solution and the antigen or control solution 
at the appropriate dilutions and volumes were added to PBS-BSA for a total volume of 1 
mL. BSA, similar to ang-2 in terms of molecular weight, also acted as a negative control 
for ang-2. Rab and hum were used as negative control for mus. The reaction mixtures 
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were incubated at room temperature for 60 minutes and then analyzed by flow 
cytometry. Baseline event distribution of QD-Ab dispersed in PBS-BSA was also 
analyzed. 
 
Results and Discussion 
 The candidate cancer biomarker protein, ang-2, was detected by flow cytometry 
to 0.5 pM concentration. Event classification between aggregates and individual particles 
was based on the observed bimodal population distribution. The forward scatter 
histogram (Figure 3.b), suggests that forward light scatter intensity of 10 a.u. is a suitable 
threshold value for this demarcation. The optimal side scatter threshold value of 10 a.u. 
was similarly identified. The fraction of events classified as aggregates were 10.1+/-
2.2%, compared to the background control aggregate formation of 1.2+/-0.2%.  The 
relationship between aggregate formation and concentration of ang-2 ([ang-2]) followed 
a log-linear correlation over the range of antigen concentrations from 0.5 pM to 100pM 
when detected with 10pM QD-AA2, and from 500 pM to 50000 pM when detected with 
100pM QD-AA2 (Figure 2). The slopes of these relationship enabled resolution of [ang-
2] between 0.5 pM and 50000 pM.  Antigen concentration resolution in the 0.5 pM to 
100 pM range is significantly higher based on the numerically greater slope of the log-
linear curve fit to the data. The maximum detected [ang-2] was 50000 pM, limited 
primarily by the concentration of ang-2 stock available. Literature reports of [ang-2] 
detected in serum range from 23 to 44 pM[24], within the high resolution range of 
measurement with this QD agglomeration technique. Similarly, serum concentrations of  
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Figure 2. Agglomeration behavior as a function of reagent concentrations. Ang-2 was 
detected down to 0.5pM using the QD agglomeration technique. The percent of total 
events detected that were categorized as agglomerates (Y axis) is a log-linear function of 
the antigen concentration (X axis). Since the number of agglomerates in the two 
component reaction is limited by the availability of either or both of the components, the 
function is linear over a limited range. Hence, the agglomeration behavior of the lower 
concentration range of ang-2 (0.5pM-100pM) was linear when detected with 10pM QD-
AA2, while the higher concentration range of ang-2 (500pM to 50000pM) exhibited a 
log-linear agglomeration behavior with 100pM QD-AA2. Data points are mean+/- 
standard deviation, n=3. 
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Figure 3. Flow cytometric data obtained by characterization of reaction mixtures. Flow 
cytometric detection of antigen is achieved by characterizing agglomerates as a fraction 
of total events. Each dot in panels a, d, c and f represents one particle or ‘event’ 
detected. Forward light scatter (FSC-H) and side light scatter (SSC-H) intensities are 
positively correlated with the size and complexity of the particles. In panels a and d, the 
ovals labeled R1 through R4 indicate standard latex beads of sizes 0.2, 0.5, 1.0, and 2.0 
microns respectively, and provide an estimate of the diameter of the QD agglomerates 
detected. Panels b and e show the change in particle size distribution upon addition of 
the antigen. Panels c and f show the relation between fluorescence intensity (FL3) and 
size (FSC-H) for the agglomerates and the native QD-GaM respectively. The multivariate 
characterization of particles in the flow cytometer enables highly sophisticated analysis of 
the particles difficult to achieve by other methods including dynamic light scattering. This 
may increase the antigen detection sensitivity via better discrimination between specific 
and non specific self assembly. Detected values for the scatter and fluorescence 
intensities are digitized in1024 channels over the range of 1-104 a.u. Typical data obtained 
from one experiment from n=3.  
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other biomarkers are in the multi-picomolar range. Hence, exceeding the sensitivity of 
ELISA significantly is not an objective of the work presented, but is being pursued 
separately. 
 Mus, which was used as a model protein in the initial experiments to optimize the 
instrument detection parameters and experimental conditions was also detected by flow 
cytometry to 0.5 pM concentration. The fraction of events classified as aggregates was 
1.0+/- 0.3%, compared to the negative control aggregate formation of 0.7+/-0.1%.  
Two different log-linear regimes were observed for aggregate formation, in a manner 
similar to that documented for ang-2. 10pM QD-GaM was used to detect mus from 0.5 
pM to 500pM.  100pM QD-GaM was used to detect mus from 500 pM to 500,000 pM.  
The slope of these relationships effectivly enabled resolution of [mus] between 0.5pM 
and 500,000 pM. The use of different concentration of QD-GaM required for addressing 
this high range of concentrations is  
 The use of multiple reactions to detect a large range of analyte concentrations is 
comparable to other antibody based techniques, where separate reactions with 
optimized protocols and stoichiometry are often required to detect low concentration 
and high concentration of the same analyte. The incubation time for these experiments 
was optimized in preliminary studies. Initial experiments were carried out to characterize 
the kinetics of agglomeration by quantifying the fraction of all events indicating large 
agglomerates at several time points up to four hours. One hour incubation period was 
determined to be optimal based on rapid initial agglomeration leading to suitably high 
detection sensitivity in this time period. Since a differential signal is obtained with 
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identical reaction conditions for all samples, this detection protocol is suitable for 
quantitative detection of antigens. 
 These results indicate that the sensitivity of the QD agglomeration technique for 
ang-2 and mus is comparable to the limit using ELISA and Western blot [22, 23]. Mass 
spectroscopy, which is currently used for recognition of protein expression patterns, 
detects protein from clinical samples only semi-quantitatively [25], and is hence not 
directly comparable with the QD agglomeration technique. Furthermore, the sensitivity 
for target analytes in mass spectrometry is also highly variable with respect to molecular 
mass of the analyte, relative abundance compared to overall sample, and other factors. 
The clinical utility of any biomarker detection method depends on both sensitivity and 
selectivity, especially in complex mixtures such as serum. Positive results can be obtained 
when data are statistically different compared to the natural population variation in 
biomarker concentration, or by establishing personalized baseline values for significant 
biomarkers. The use of multiple biomarkers correlated with a single physiological state 
also increases predictive power of biomarkers significantly, compared to that of a single 
biomarker[26-29]. The suboptimal performance of prostate specific antigen (PSA) as a 
single marker for diagnosing and prognosing prostate cancer is a strong motivation for 
moving towards a multiple biomarker strategy for detecting disease. 
 The high sensitivity and selectivity of this technique is remarkable, especially 
considering the single step reaction mechanism, the short time required for the process, 
and ease of implementation compared to conventional techniques such as ELISA, 
Western Blot, 2D-GE, and mass spectrometry. These advantages suggest the possibility 
of further developing this method for sensitive, rapid, and economical point-of-care 
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proteomic diagnostics. The possibility of harnessing other types of intermolecular 
recognition reactions such as DNA-DNA, ligand-receptor, and aptamer-target suggests 
wider utility of this method, and is currently under investigation. Since the QD-Ab 
construct is modular, other types of nanoparticles may also be used in place of QDs and 
could enable alternate detection methods. 
 Polyvalent molecular recognition interactions between the reactants are required 
for the formation of self assembled structures in this manner. If only monoclonal 
antibodies were used, the QD-Ab-Antigen structures formed would be similar in size to 
the constituents, and thus harder to detect. To achieve polyvalent interactions, we have 
utilized quantum dots conjugated with polyclonal antibodies. However, monoclonal 
antibodies are also likely to be useful if the target antigen presents multiple copies of the 
epitope on its surface. While quantum dots with a single emission wavelength were used 
in these experiments to detect a single protein, preliminary evidence suggests that 
multiplexed protein detection using multiple quantum dot populations is also feasible. 
The studies reported here were conducted in samples of controlled and well-known 
composition. Biomarker detection capabilities in complex mixtures such as blood plasma 
are unknown. The performance of this approach for sensing biomarkers in clinical 
samples may be partially inferred from the control data and from the well known 
characteristics of immunorecognition methods such as ELISA which has a number of 
commonalities with the QD agglomeration method. Additional studies are required to 
characterize biomarker detection in serum using functionalized QDs and these are under 
way, but are not part of this work. 
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 The percentage of self assembled agglomerates in a colloidal mixture can 
presumably be determined by flow cytometry using a variety of parametric 
combinations. We have utilized a combination of forward light scatter threshold and side 
light scatter threshold to demarcate agglomerates from smaller particles. The fraction of 
total events corresponding to the agglomerated sub-population serves as a metric 
correlated with antigen concentration. An example of the significant difference in the 
approximate size distribution of QD agglomerates mediated by ang-2 antigen in 
comparison with the BSA control appears as panels 3.b and 3.e, respectively.  Forward 
light scatter intensity (FSC) is an approximate surrogate that is positively correlated with 
event diameter, suggesting that the addition of ang-2 mediates the formation of many 
aggregates significantly larger in diameter than can be triggered by the BSA control 
antigen.  The correlation between forward light scatter and event size for this instrument 
is identified in panels 3.a and 3.d as the gated regions R1, R2, R3 and R4, which 
correspond to latex calibration sphere diameters of 0.2, 0.5, 1.0, and 2.0 μm, 
respectively.  Events of these sizes are significantly larger than the diameter of antibody-
functionalized QDs (Figure 5, approximately 0.045 μm, or 45 nm).  Quadrant gating in 
the forward light scatter and side light scatter (SSC) space highlights events with 
diameters greater than approximately 0.5 μm (500 nm).  The events in the upper right 
quadrant are highlighted in red and are defined to be QD agglomerates in this method.  
This gating also corresponds to the bimodal population distribution in the aggregated 
sample, as seen from the FSC histogram (panel 3.b). The addition of 10pM ang-2 
resulted in an agglomerate sub-population of 44% (panel 3.a), significantly greater than 
the 1.2% mediated by addition of the control BSA antigen (panel 3.d).  The agglomerates 
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identified by forward light scatter intensity are also fluorescent in the FL3 wavelength 
range (650nm and longer), consistent with the fluorescence of QDs with an emission 
maxima of 705 nm (panels 3.c and 3.f).  The fluorescence emission intensity of QD 
agglomerates is not a direct summation of the fluorescence emission intensities of each of 
the estimated 2500 QDs per agglomerate, suggesting that modulation of the excitation 
and/or fluorescence emission occurs in these agglomerates.  Based on the expected 
structure of the agglomerates, the QD are likely to be separated by about 20nm. Hence, 
the cause of the quenching is unlikely to be based on fluorescence resonant energy 
transfer[30, 31]. However the formation of a network of QDs may reduce the intrinsic 
fluorescence quantum yield of each QD through modulation of the nanoscale surface 
characteristics. The large size and complex structure of the agglomerates may shield 
many of the QDs from the excitation light source, as well as trap emitted radiation, and 
hence part of the reason for the observed fluorescence quenching could be optical 
screening. While the exact mechanism of the fluorescence quenching is unclear, 
quenching upon agglomeration was confirmed separately by measuring the bulk 
fluorescence intensity (Figure 4) during the agglomeration reaction. The bulk 
fluorescence of reaction mixtures with different [mus] was observed over time in a plate 
reader. The fluorescence intensity of the mixture decreased with time for 
[mus]=666nM, the highest concentration of antigen used, while the reaction mixture 
with the negative control [hum]=666nM did not exhibit decreasing bulk fluorescence 
intensity. 
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Figure 4. Modulation of bulk fluorescence of reaction mixture due to antigen induced 
self assembly of QD-Ab conjugates. The solution fluorescence intensity of 1nM QD-GaM 
solution decreases after addition mus, consistent with aggregation-modulated 
fluorescence quenching observed by flow cytometry. The largest decrease is seen in the 
sample containing the highest concentration of mus. Flow cytometric characterization of 
the same sample showed very high fraction of agglomerates. Optical screening of 
excitation and emission due to the large size and complex structures of the agglomerates, 
as well as modulation of nanoscale surface properties upon agglomeration are thought to 
be responsible for the observed fluorescence quenching. Data from one experiment, 
typical of the n=3. 
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Figure 5. Dynamic light scattering characterization of antigen induced nanoparticle self-
assembly. Nanoscale QDs surface functionalized with GaM antibody self-assemble into 
microscale agglomerates mediated by polyvalent antigen (red peak at 2,000 nm).  
Addition of nonspecific antigen (hum) fails to mediate large agglomerate formation (lack 
of grey peak > 700 nm). 
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 The FL3-FSC representation (3.c, 3.f) provides an example of how the 
multiparametric data obtained from the flow cytometer enables sophisticated analysis of 
the sample, and may increase signal to noise ratio and sensitivity of detection. In this 
instance, two different populations of particles appear in the upper-right quadrant of the 
FSC-SSC space (3.a) but can not be distinguished from each other. However, in the 
forward scatter-fluorescence space (3.c), the non-specific agglomerates can be easily 
separated from the antigen mediated agglomerates. Most QD-AA2-ang2 agglomerates 
have high forward scatter and low fluorescence intensity (panel 3.c). While the volume of 
these agglomerates is about 250-fold greater than the individual QD-AA2 agglomerates, 
the fluorescence intensity is only 3-fold greater. A very small fraction of particles (less 
than 0.1%) in this agglomerated sample show high FSC as well as high FL3 intensities. 
These anomalous events are likely due to electronic noise as well as non-specific 
agglomeration between QD-AA2 conjugates. While these two populations appear in the 
same region on the FSC-SSC plot (3.a), they can be easily distinguished from each other 
in the FL3-FSC representation (3.c). In samples where a higher concentration of the QD-
Ab conjugate is used, the number of these anomalous events is even larger. Combined 
with the smaller overall fraction of the agglomerate population in these samples, the 
increased utility of the multiparametric characterization to increase signal to noise ratios 
and detection sensitivity is apparent. 
 The graphical representation of the flow cytometric data (Figure 3) also suggests 
that further improvement in the detection sensitivity may be achievable by fine tuning the 
threshold used here to demarcate agglomerates from non-agglomerates. Furthermore, 
while measuring the fraction of particles larger than a threshold is a simple way of 
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quantifying agglomeration, it does not take into account the full complexity of the self-
assembly phenomenon. Detection sensitivity and resolution may also improved by 
creating sophisticated data processing algorithms that correlate antigen concentration 
with other measurable parameters such as agglomerate size distribution, population 
distribution in the light scatter vs. fluorescence intensity space, and kinetic measurement 
of the agglomeration. Using flow cytometry, these parameters can be easily measured 
for each of the particles. This may enable sophisticated and quantitative characterization 
of the agglomeration and hence sophisticated, automated, and simultaneous detection of 
multiple antigens. 
 Other parameters including antigen-antibody binding energies, fluid mixing energy 
and duration, and presence of non-specific reactants are also important to the 
characteristics of the agglomerates formed. In this work, time and relative concentration 
of QD and antigen was optimized based on measured aggregate formation, but the 
optimization of the reaction with respect to the other parameters is ongoing. The 
current data represents a system in equilibrium, but the final state may not provide 
optimum biomarker detection sensitivity. The kinetics of QD aggregate formation are 
presumably influenced in a multivariate way that is currently under investigation.  
Temporal differences in QD aggregate formation mediated by specific and nonspecific 
interactions are expected based on the range of immunorecognition kinetic parameters.  
The translation of a traditional kinetic ELISA approach to the present system is 
particularly elegant since each QD aggregate event is time-stamped during flow 
cytometric detection.  In this way, additional discrimination between QD aggregation 
mediated by specific biomarker and nonspecific interactions may be achieved, improving 
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the sensitivity and selectivity of the proposed method. Parameters such as temperature, 
pH and ion concentration are also expected to have some effect on the agglomeration 
behavior. The characterization of the effects of these parameters is currently under way, 
however, the current reaction media was chosen to closely approximate the properties 
expected from a physiological sample such as serum. 
 In addition, the flow cytometric detection strategy influences the sensitivity of 
QD aggregate detection; optimization of triggering and amplification settings has been 
performed to obtain the results presented here, but additional improvements are likely 
with continued refinement. Preliminary investigation indicates that increased laser 
power, shorter excitation laser wavelengths, and better detection optics may provide 
significantly improved biomarker detection sensitivity. Improved understanding of QD 
aggregate detection by flow cytometry, a nonlinear optical process, may yield new 
approaches to improved biomarker detection performance through adjustment of 
instrument settings. 
 The AA2-ang2 and GaM-mus systems were both characterized by flow cytometry 
as well as DLS. Particle size and aggregation data measured by both modalities correlate 
well within each system. The data from flow cytometric characterization of the AA2-
ang2 system and DLS characterization of GaM-mus system are shown in the interest of 
brevity. Preparation of the QD-Ab conjugates was monitored using a DLS particle sizer. 
Successful preparation of the QD-GaM conjugates was indicated by a shift in particle 
diameter from 25nm representing the unmodified QD to 45nm indicative of the 
formation of QD-GaM conjugates (Figure 5). This shift was not observed when QD 
were treated with the same volume of TBS-BSA. A similar change in particle size 
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distribution was observed upon conjugation of anti-ang-2 and QD. DLS measurements 
were also used to verify agglomeration in the presence of the antigen. The addition of 
Mus to the QD-GaM solution resulted in the formation of a new peak at 2000nm, 
indicating the formation of large agglomerates. The agglomerates are up to two orders of 
magnitude larger than the individual constituents, and as verified also by other methods 
including flow cytometry and electrical sensing zone method (data not shown). When the 
negative control antigen (hum) was added, this large peak was not observed in the DLS 
data, verifying the hypothesis that agglomeration occurs primarily by specific antibody-
antigen recognition, rather than by other non-specific interactions. 
 
Conclusions 
 In conclusion, we have demonstrated a novel antigen detection technique based 
on fundamental nanoscale phenomena. This technique has several advantages over 
conventional antigen detection strategies due to the use of solution phase 
biofunctionalized quantum dots and a microfluidics based detection strategy. Sensitive 
detection was carried out completely in the fluid phase, in a single step and with minimal 
incubation. In this work, we have separately detected two different proteins with high 
sensitivity and specificity. Simultaneous detection of multiple proteins from a complex 
mixture such as a serum is currently being investigated. The cross reactivity of antibodies 
as well as non-specific reactions both lead to agglomeration, and may limit sensitivity in 
these scenarios. These limits may be overcome through use of sample processing 
techniques from conventional immunorecognition methods as well as sophisticated 
methods for acquisition and processing of the data, including kinetic measurements, 
 44 
which is not possible with other detection methods. Our technique requires minimal 
sample volume, is amenable to multiplexing, automation and implementation in a 
microfluidic chip, and is completely modular, making it an ideal candidate as a platform 
technology for frequent and low cost proteomic testing and monitoring of cancers, as 
well as an advanced point-of-care diagnostic based on a diverse array of intermolecular 
recognition based biomarker sensing. 
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CHAPTER III 
 
SENSITIVE AND MULTIPLEXED DETECTION OF PROTEOMIC ANTIGENS VIA 
QUANTUM DOT AGGREGATION 
 
Summary 
 A rapid, single step, solution phase method for quantifying multiple proteomic 
biomarkers is described. Nanoscale quantum dot-antibody conjugates self-assemble into 
microscale aggregates in the presence of a specific antigen through antibody-antigen 
molecular recognition. These aggregates are easily discriminated from the individual 
components by flow cytometry. Quantum dot aggregates can be quantified and 
correlated to the antigen concentration. Two quantum dot populations with distinct 
emission spectra are used for detecting two proteomics antigens in a single reaction 
volume. Multiplexed detection of vascular endothelial growth factor A and angiopoietin-2 
is demonstrated at the physiologically relevant, picomolar concentration range. Non-
multiplexed detection of the antigens is also demonstrated, with a femtomolar sensitivity 
limit. This technique may be optimized for low cost early detection and frequent 
screening of cancers and other diseases as well as detection of the biological response to 
therapy. 
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Introduction 
 Research in functional genomics and proteomics is leading to the discovery and 
clinical validation of a large number of molecular biomarkers. These markers are thought 
to be associated with specific diseases, variants and disease progression states. 
Biomarker-based understanding of a many pathologies is poised to significantly improve 
patient outcomes for a many major diseases including cancers, Alzheimer’s disease, 
vascular pathologies and others. It is expected that techniques based on molecular 
biomarkers will be used for screening, early diagnosis, frequent monitoring, and 
personalized therapy management of diseases in the coming decades. 
 Conventional protein detection technologies that are currently used in research 
settings are not optimal for frequent diagnostic applications. These methods, such as 
mass spectrometry, ELISA assays, 2D-PAGE and others, are used for identifying and 
validating proteomic biomarkers, but fall short on one or more of the important 
parameters of speed, sensitivity, multiplexing capability or production of quantitative data. 
Perhaps most important from the point of view of clinical utility, ease of implementation 
and cost are not favorable for these techniques due to the requirement for highly trained 
personnel and difficulties in automation. 
 A variety of nanoscale and microscale technologies have been proposed and 
demonstrated over the last few years for efficient and cost effective detection of 
molecular biomarkers from biological samples. These techniques take advantage of a 
variety of nanostructures including micro-cantilevers[1], metallic, semiconductor or 
polymer nanoparticles[2], carbon nanotubes[3] and more[4]. 
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 In a recent publication, we have demonstrated a sensitive, rapid, single step, 
solution phase antigen detection technique based on nanoparticle self assembly and flow 
cytometry[5]. Quantum dots (QDs) were conjugated with polyclonal antibodies (Ab) 
using a streptavidin-biotin interaction[6]. In the presence of the appropriate antigen 
molecules (mouse IgG and angiopoietin-2) these  QD-Ab conjugates rapidly self-
assembled into colloidal structures with sizes one to two orders of magnitude larger than 
the constituents (quantum dot-antibody (QD-Ab) conjugates and proteomic antigens). 
The proportion of these self assembled structures to the total events counted by flow 
cytometry was shown to be a function of the relative concentrations of the QD-Ab 
conjugates and the antigen molecules, among other factors. The quantification of these 
microscale aggregates was easily achieved on a conventional flow cytometer. We also 
proposed that due to the multiparametric characterization capabilities of flow 
cytometers, it would be possible to detect multiple antigens from a single sample using 
QDs with distinct emissions spectra. 
 In the present paper we extend our previous work to demonstrate multiplexed 
detection of two proteomic antigens. Angiopoietin-2  and vascular endothelial growth 
factor A were detected simultaneously in the 1 pM to 100 pM concentration range using 
two QD-Ab conjugates with distinct emissions spectra. The detection sensitivity limit for 
non-multiplexed detection is also improved, by an order of magnitude improvement 
compared to the previous work, to 50 fM. The detection of two distinct aggregate 
populations was achieved by optimizing flow cytometric data acquisition parameters to 
minimize the baseline noise that occurs due to non specific antigen-antibody reactions as 
well as uncertainties in measuring QD aggregate fluorescence with the flow cytometer. It 
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is expected that multiplexed antigen detection sensitivity can be improved to approach 
the individual antigen detection sensitivity by improving sample preparation and 
modifying data acquisition parameters. 
 Detection of pathogens by molecular recognition-based self-assembly was 
proposed as far back as 1956 in the form of the latex agglutination test[7], which is still 
used for detecting bacteria[8-10], and for determining blood types, but is unsuitable for 
sensitive detection of low concentration small molecules. Nanoparticle-based variants of 
the agglutination test have been demonstrated for small molecules such as DNA 
fragments[11] and proteins[12]. In both these demonstrations, the change in plasmon 
resonance due to self assembly of the metal nanostructures was spectroscopically 
monitored. Small molecules have also been detected using quantum dots using antibody-
mediated coincidence of multiple quantum dots with different emission wavelengths[13, 
14]. Flow cytometric microsphere-based immunoassay (FMBA) has been proposed for 
the simultaneous detection of multiple proteins[15, 16]. FMBA assays are essentially 
antigen capture sandwich immunoassays on microspheres, and use microsphere size 
and/or fluorescence intensity as discriminating characteristics for multiplexing. Compared 
to these techniques, antigen mediated quantum dot agglomeration demonstrated here, 
combined with flow based detection on a microfluidic device, has the potential to offer 
better sensitivity, ease of use, speed, and cost of testing. 
 The multiplexed detection of two candidate cancer biomarkers involved in 
angiogenesis is demonstrated in this paper. It has been demonstrated that the use of 
biomarker panels – multiple biomarkers evaluated concurrently - results in a significantly 
improved diagnostic and prognostic performance compared to the use of a single 
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proteomic biomarker single discriminating protein [17-19]. One of the biomarkers 
evaluated in this paper is vascular endothelial growth factor A (VEGF), a 21 kDa protein. 
VEGF is a strong angiogenetic factor, and elevated serum levels have been detected in 
melanoma, pituitary, colorectal, breast, and prostate cancers[20]. In the control 
population, mean plasma VEGF concentration quoted in the literature is 1-9 pM, and in 
the presence of cancer, the mean value increases to 15-24 pM, based on the type and 
stage of the cancer studied[20, 21]. The other biomarker evaluated in this paper is 
angiopoietin-2 (ang-2), a 66kDa protein, is involved in neo-angiogenesis[22, 23]. Due to 
the importance of neo-angiogenesis in the proliferation of various cancers, ang-2 is a 
protein of interest as cancer marker and therapy target[24, 25] and has also been shown 
to correlate with the invasiveness and growth of various cancers[22, 26] The mean 
normal physiological plasma concentration of ang-2 is 22 pM for females, while elevated 
concentration for female breast cancer patients is 30 pM. In males, the mean 
concentration in control population is 20 pM, and mean elevated concentration for 
prostate cancer patients is about 40 pM[27]. 
 The molecular recognition mediated self assembly utilized in this technique is not 
directly affected by the choice of nanoparticle in the nanoparticle-antibody conjugate 
probe used. However, QDs present an ideal combination of properties that make them 
an excellent choice for this application. The unique fluorescence properties of QDs [28-
31] facilitate detection of aggregates as well as discrimination from other 
microparticulates that may be present in solution. Surface modification for biological 
applications - including conjugation with proteins and antibodies [6, 32, 33] and 
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multiplexed biological applications [34-36] have been well explored. Hence, QDs are 
widely recognized to be suitable for ex-vivo diagnostic technology[37, 38]. 
 
Experimental 
 
Materials 
 Streptavidin-coated quantum dots with 705 nm (QD705, #Q10161MP) and 585 
nm (QD585, #Q10111MP) fluorescence emissions were purchased from Invitrogen 
(Carlsbad, CA) and used as received. Biotin conjugated anti-angiopoietin-2 polyclonal 
antibody (aA2, #BAF623), biotin conjugated anti-VEGF polyclonal antibody (aVEGF, 
#BAF293), recombinant human angiopoietin-2 (Ang2, #623-AN), and recombinant 
human vascular endothelial growth factor A (VEGF, #293-VE) were purchased from 
R&D Systems (Minneapolis, MN), reconstituted in Tris-buffered saline (TBS) containing 
0.1% bovine serum albumin (BSA) and stored at -20oC. Appropriate dilutions of all 
antibodies and antigens were prepared in phosphate buffered saline (PBS) with 0.1% 
BSA immediately prior to use. All buffers were filtered through 0.2 μm filters. All other 
reagents were ACS reagent grade. Deionized water with 18 MΩ resistance was used for 
preparing buffers. Flow cytometric measurements were carried out on Beckton 
Dickinson (BD) FACSCalibur. 
 
Quantum dot-antibody conjugation 
 Using the optimized protocol described previously[5], quantum dot-streptavidin 
conjugates (QD) and biotinylated anti-angiopoietin-2 polyclonal antibody (aA2) or anti-
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VEGF polyclonal antibody (aVEGF) were mixed in PBS-BSA at QD:antibody molar ratio 
of 1:3 and 1nM QD concentration. The conjugate was used as synthesized after 
incubation for 30 minutes at room temperature.  
 
Antigen Induced Self Assembly 
 The QD-antibody (QD-Ab) conjugate solution and the antigen or control solution 
at the appropriate dilutions and volumes were added to PBS-BSA for a 500 μL final 
volume. BSA, similar to ang-2 in terms of molecular weight, acted as a negative control 
for Ang2 and VEGF. The reaction mixtures were incubated at room temperature for 60 
minutes and then analyzed by flow cytometry. Baseline event distribution of QD-Ab 
dispersed in PBS-BSA was also analyzed. Non-multiplexed detection was carried out by 
reacting 5 fM to 500 pM VEGF with 10 pM QD705-aVEGF conjugates, and 5 fM to 500 
pM Ang2 with 10 pM aA2, both in 500 μL final volumes. Ten different concentration 
values of each antigen were examined, and three datasets of each antigen were acquired 
from three different experiments. For multiplexed detection, the antigen mixture was 
prepared in PBS-BSA by sequentially adding appropriate volumes and dilutions of the 
VEGF and Ang2 stock solutions. The mixture of QD705-aVEGF and QD585-aA2 were 
added to these antigen solutions for a final concentration of 10 pM of each of the QD-Ab 
populations in 500 μL final volumes. Experiments with 5 fM to 500 pM VEGF 
concentrations with no Ang2, 1 pM 10 pM or 100 pM Ang2 were carried out. The 
inherent variability of the QD-Ab dilution caused a large effect on the fraction of 
agglomerates observed. Hence, only the datasets with base QD-Ab count within 
2000+/-200 were utilized for analysis. 
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Flow cytometric characterization 
 The size, fluorescence and number of the aggregates in the incubated samples 
were characterized by flow cytometry. The basic flow cytometric protocol followed was 
similar to the one used in our previous publication[5]. Briefly, signal amplification for the 
flow cytometer parameters forward scatter (FSC) and side scatter (SSC) detectors and 
fluorescence detectors with 585+/- 21nm (FL2) and 650nm long pass filters (FL3) were 
optimized for characterizing small particles. The forward scatter and side scatter 
performance was calibrated by using 0.2, 0.5, 1, 2 and 2.8 μm latex calibration particles. 
In Figure 1.a, the regions indicated by R1, R2, R3, R4 and R7 correspond to the 0.2, 0.5, 
1, 2 and 2.8 μm latex calibration particles respectively. Aggregates were defined as 
particles with forward scatter greater than 10 a.u. This corresponds to a nominal size 
greater than approximately 0.5 μm, as well as the observed differentiation of the 
individual QD-Ab conjugates from the large aggregates inherent in the agglomeration 
process and the measurement protocol[5]. The data was acquired at low flow rate (12 
+/-3 μL/min) for one minute, and either the FL2 or FL3 channels individually for non-
multiplexed detection or both sequentially for multiplexed detection were used as 
triggers to minimize noise from non-fluorescent micro-particles in the reaction mixture. 
In our previous publication, the fraction of aggregates was defined as the event fraction 
appearing in the upper right quadrant (UR) of the FSC vs. SSC plot. Since the aggregates 
appear in this quadrant regardless of the fluorescence intensity in the FL2 and FL3 
channels, detection of multiple QD populations requires an approach influenced by QD 
fluorescent color. To achieve multiplexed detection, the fraction of aggregates was  
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1.a 
 
1.b 
 
1.c 
 
 
Figure 1: Characterization of multifluorescent reaction mixture by flow cytometry. The 
QD-Ab:antigen aggregates were characterized by flow cytometry. The panels show the 
raw data acquired from a multiplexed sample containing 10 pM Ang2 and 10 pM VEGF as 
well as the appropriate QD-Ab conjugates. Panel a shows that optimized flow 
cytometric detection parameters enable the resolution of individual QD-Ab conjugates 
and small aggregates (black dots, bottom left quadrant) from the micron scale aggregates 
(red dots, upper right quadrant). The regions labeled R1, R2, R3, R4 and R7 indicate 0.2, 
0.5, 1, 2 and 2.8 μm calibration particles respectively. Panels b and c show the FL vs. 
FSC data representation of the events representing aggregates acquired with FL3 and 
FL2 triggers, respectively. The regions R8 and R9 demarcate areas on these charts 
corresponding to the aggregates (FSC>10, as in panel a). The events in R8 and R9 are 
counted as single antigen aggregates mediated only by VEGF and Ang2 respectively. The 
bottom edges of R8 and R9 are specified such that false positives are reduced but not 
more than 1% of the events in an equivalent non-multiplexed experiment are counted as 
false-negative. 
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instead characterized in the FSC vs. FL3 plot in region R8 for the QD705 quantum dot 
population (Figure 1.b) and FSC vs. FL2 plot in region R9 for the QD585 quantum dot 
population (Figure 1.c). The lower boundary of regions R8 and R9 was raised to 
minimize the QD585 aggregates count in the QD705 population and vice versa. The 
gating was adjusted to limit this loss of aggregate events to 1% of total number of events 
in the triggering population, as determined by characterizing non-multiplexed samples. 
 Statistical analysis of the datasets was carried out using the SigmaStat 3.1 software. 
The t-test was utilized to determine whether experimental parameters, including the 
concentration of the non-specific antigen in the multiplexing mixture, signal acquisition 
optimization and gating geometry, had a statistically significant effect on the relationship 
between antigen concentration and agglomerate percentage. When t-values for two 
datasets compared are close to zero, the difference between the two datasets and the 
effect of the experimental parameters is statistically insignificant[39]. 
 
Results 
 Non-multiplexed detection of VEGF and Ang2 was achieved from 50 fM to 100 
pM. Figure 2 shows the correlation between aggregates, as a percent of total number of 
events counted, and antigen concentration. In these non-multiplexed aggregation 
experiments, the concentrations of either antigen from 50 fM to 100 pM produced a log 
linear correlation with the fraction of events detected as aggregates. The two 
correlations have statistically different slopes: 6.96+/-0.30 for Ang2 and 4.60+/-0.21 for 
VEGF. The background aggregate concentration caused by non-specific assembly of QD-
Ab conjugates in the PBS-BSA buffer has a value of 1.39+/-0.3% for QD705-aVEGF and 
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1.56+/-0.38% for QD585-aA2. A t-test comparison of the QD585-aA2:Ang2 
agglomeration percentage from 500fM to 100pM [Ang2] in the current data and in the 
previously published data[5] indicates no statistically significant difference based on a t-
value of 0.073. Over the range of antigen concentrations measured, the two lower 
antigen concentration values of 5 fM and 10 fM generate aggregates that are within three 
standard deviations of the background non-specific aggregate count. The samples with 
500 pM antigen concentration also deviate from the log-linear correlation.  
 Quantitative multiplexed detection of both antigens in the physiologically relevant 
concentration range was also achieved. Multiplexed detection of the two antigens was 
demonstrated over the 1 pM to 100 pM concentration range. The relationship between 
the VEGF concentration and percent aggregates (R8%) is log linear even in the presence 
of Ang2 (Figure 3). The slope +/- standard error values of the correlation for the 
multiplexed detection of VEGF at 0, 1, 10 and 100 pM Ang2 are  3.9+/- 0.33, 4.0 +/- 
0.28, 4.1+/- 0.33 and 4.3 +/- 0.35 respectively. The slope for non-multiplexed detection 
of VEGF is 4.6 +/- 0.31. The t-test comparisons of the QD705-aVEGF:VEGF aggregate 
percentages from 1pM to 100 pM [VEGF] in all experiments have a range of t-values 
from -0.039 to 0.077, indicating no statistically significant effect of Ang2 concentration on 
VEGF detection (Table 1). The VEGF-negative control experiments with Ang2 added at 
the appropriate concentration to the multiplexed QD-Ab mixture determined the limit 
of VEGF detection. The highest percentage of non-specific aggregates + three standard 
deviations (P=99.7%), formed in the negative control experiment with 100 pM Ang2 
resulted in a sensitivity limit of 1 pM for VEGF. The background aggregate percentage 
increased with increasing Ang2 concentration. At 100 pM Ang2 background non-specific 
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aggregate percentage was 6.4 +/- 0.87%, compared to the background aggregate 
percentage in the non-multiplexed experiments (1.4 +/- 0.1%). 
 Quantitative multiplexed detection of Ang2 was also achieved from the same set 
of samples, as measured by R9 aggregate% (Figure 4). The change in VEGF 
concentration in the samples does not have a statistically significant effect on the 
detection of Ang2 in the range of concentrations examined. The t-values for these data 
range from -0.046 to 0.043.The t-tests for the multiplexed sample datasets were carried 
out for R9% values of the four concentrations of Ang2 – 0, 1, 10 and 100 pM, for each 
concentration of VEGF and for the non-multiplexed Ang2 detection data set. 
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Figure 2: Non-multiplexed detection of VEGF and Angiopoietin-2. A sensitivity limit of 
50 fM was achieved when the antigens were reacted with 10 pM QD-Ab. The 
relationship between antigen concentration and fraction of aggregates detected was log-
linear for both antigens, but with statistically different slopes: 6.96+/-0.30 for Ang2 and 
4.60+/-0.21 for VEGF. A t-test comparison for the current Ang2 data with previously 
published data[5] indicates no statistically significant difference. Thus, the change in gating 
strategy to accommodate multiplexed detection has no effect on the quantification of 
aggregates. Percent aggregates formed for antigen concentrations less than 50 fM were 
within three standard deviations of the mean non-specific aggregate count in the absence 
of the specific antigens, i.e. the background noise. Aggregate formation in the presence 
of 500pM antigen was close to background level, suggesting a quenching of the 
agglomeration process due to the excess antigen. Data represents the mean and 
standard deviation of values observed from n=3 experiments. 
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Figure 3: Multiplexed detection of VEGF. 10 pM QD705-aVEGF conjugates were 
incubated with of 0, 1, 10, and 100 pM Ang2 and 10 pM QD585-aA2 conjugates. The 
log-linear VEGF detection correlation is statistically equivalent across Ang2 
concentrations as determined by t-tests. The correlation between aggregate population 
and VEGF concentration was also statistically identical to the non-multiplexed antigen 
detection experiments. The fractions of QD705-aVEGF:VEGF aggregates, as well as the 
background event count, were determined by flow cytometry from region R8. The 
detection scheme was effective in the physiologically relevant range of 1-100 pM. The 
VEGF detection sensitivity limit is 1 pM due to the background noise (green data points 
at the bottom of the chart) resulting from nonspecific interactions between both the 
QD-Ab conjugates, as well as non-specific QD-Ab:antigen interactions. Data represents 
the mean and standard deviation of values observed from n=3 experiments. 
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Figure 4: Multiplexed detection of angiopoietin-2. 1, 10 and 100 pM angiopoietin-2 in 
the presence of 1, 5, 10, 50, and 100 pM VEGF. The varying VEGF concentration does 
not have a statistically significant effect on the quantitative detection of Ang2, as 
determined by t-tests. The data is from the same samples as in Figure 3, the fractions of 
QD585-aA2:Ang2 aggregates were quantified in region R9 of the FL2 vs. FSC data space. 
The percent Ang2 aggregates in the multiplexed detection experiments are also 
statistically identical to the percent aggregates in the non-multiplexed experiment, based 
on t-test comparisons. Data represents the mean and standard deviation of values 
observed from n=3 experiments. 
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Table 1: t-test comparison of non-multiplexed VEGF detection and multiplexed VEGF 
detection at various angiopoietin-2 concentrations. 
 
t-value 
Non-
Multiplex
0 pM 
Ang2 
1 pM 
Ang2 
10 pM 
Ang2 
100 pM 
Ang2 
100 pM 
Ang2 
0.043 0.077 0.007 -0.017 0 
10 pM Ang2 
0.062 0.097 0.025 0  
1 pM Ang2 
0.037 0.073 0   
0 pM Ang2 
-0.039 0    
Non-
Multiplexed 
0     
 
The t-values are close to zero, indicating that there is no statistically significant difference 
between these datasets. Thus, the presence or absence of QD585-aA2 and Ang2 does 
not significantly affect the VEGF detection curve. Each cell in the array shows t-test 
performed between the mean percent agglomerates dataset for 1pM to 100 pM [VEGF], 
and [Ang2] as indicated in header of the intersecting row and column. 
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Discussion 
 Multiplexed detection of proteomic antigens with molecular recognition-
mediated nanoparticle self-assembly is feasible in the physiologically relevant 
concentration range. Since this technique is based on antibody-antigen interaction, it is 
expected that detection sensitivity similar to that demonstrated here would be 
achievable for a variety of proteomic biomarkers subject to the dissociation constant (kd) 
ranges for the specific polyclonal antibody-biomarker pairs. The reproducibility of the 
equilibrium aggregate percentage suggests the feasibility of self-assembly based 
quantification of antigens, even though individual QD-Ab:Ag interactions are presumably 
random. The fundamental feasibility of quantum dot self-assembly for multiplexed 
protein quantification has been demonstrated here as a proof of concept. Significant 
improvements in the materials and methods, including adoption of microfluidic based 
instrumentation, is appropriate to translate technique as a routine clinical, personal, or 
research proteomic profiling tool. The results also establish that the adjustments made to 
the data acquisition process and gating strategies to enable multiplexed detection do not 
have a statistically significant effect on the quantification of aggregates. 
 As expected from the mechanism of antibody-antigen interaction, the presence of 
a large excess of antigen in the solution rapidly associates with antibody binding sites and 
inhibits the QD aggregation process. This is manifested in the low aggregate count for 
both antigens in the non-multiplexed experiments at the highest concentration (500 pM, 
Figure 2). This antigen concentration corresponds to a 50:1 antigen to QD-Ab ratio. At 
the 3x antibody:QD molar ratio used to prepare the QD-Ab conjugates, the actual ratio 
of antigens to antibody binding sites is approximately 8:1. This is comparable to the 10-
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fold molar excess of antigens commonly used for antibody blocking in conventional 
antibody-antigen based reactions. Due to this effect, for clinical implementation, 
optimized QD-Ab concentrations may be required for each target antigen based on the 
expected concentration range. We have previously demonstrated that it is possible to 
extend the dynamic range of this technique by using multiple QD-Ab concentrations[5]. 
Such multiple antigen:QD-Ab stoichiometries can be easily implemented at low cost on 
second generation microfluidic-based instrumentation 
 Another interesting feature observed from the non-multiplexed data is that the 
lower limit of detection is far lower than what would be expected based on simple 
stoichiometric considerations. Using the 10 pM QD-Ab concentration, it is possible to 
detect 50 fM antigen in the non-multiplexed reaction, an antigen:QD-Ab ratio of 1:200, 
or antigen:antibody binding site ratio of 1:600. While such ratios are not uncommon in 
conventional antibody-anigen based reactions, stoichiometric considerations suggest that 
the large excess of antibody binding sites would limit the formation of large aggregates. 
However, the presence of a statistically significant number of aggregates at this antigen 
concentration indicates that the aggregate formation is strongly favored. This may result 
from the lower free energy of the aggregates compared to the individual components. 
Theory-based calculations and simulations will be performed to test this hypothesis, but 
are not a part of this experimental study. 
 The difference in the fraction of agglomerates observed for the two antigens at 
identical concentration, and consequently, the different slopes for the two detection 
curves, indicate that the number of aggregates formed is affected not only by QD-
Ab:antigen ratio, but also by other characteristics, potentially including antibody-antigen 
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affinity and the size of the antigen. We have also reported this effect previously – the 
slope for the detection curves of Ang2 and mouse IgG is different[5]. Similar effects are 
also observed in other antibody based protein detection methods. For example, different 
characteristic detection curves are obtained in commercial ELISA mothods for different 
antigen-antibody pairs. 
 We have also confirmed that multiplexed detection of both of the antigens tested 
is feasible in the physiologically relevant concentration range. The aggregate fraction is 
not significantly affected by the presence of the multiple antigens in the reaction mixture. 
T-tests show that the effect of multiplexing on the detection curve within the 1 pM to 
100 pM concentration range is statistically insignificant for both the antigens. The effect 
of multiple antigens in the reaction mixture on the agglomeration of a QD-Ab:antigen 
pair is of critical significance for a multiplexed antigen profiling technique. Since there are 
numerous antigens present in a complex biological sample, measurement robustness 
against these non-specific reactions is an important factor in determining the suitability of 
a technique for application as a multiplexed diagnostic. The antigen sensitivity limit is 
reduced in a multiplexed sample relative to the sensitivity in non-multiplexed equivalent 
due to increased background noise. The adverse characteristic may be through antibody-
antigen cross reactivity and/or non-specific nanoparticle interactions. In the technique 
demonstrated here, the characterization of the aggregates was carried out with flow 
cytometry, and the aggregates were counted in the FL vs. FSC space. The aggregates 
with high intensity in one fluorescence channel register a low fluorescence aggregates in 
the detection channel. The gating strategy enables the exclusion of a large number of 
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these false positive detections. Once the gating strategy is optimized, it need not be 
adjusted for the set of antigens. 
  
Conclusion 
 In summary, we have established that the quantum dot agglomeration-based 
protein detection technique is capable of multiplexed quantification of proteomic 
antigens. The protein detection is currently carried out simultaneously for two antigens 
at physiologically relevant concentrations in a simple physiological buffer. Further 
optimization of the reagents and biological samples, as well as of the incubation and data 
acquisition protocols, may provide the ability to quantify proteins from physiological 
samples. These optimizations may also improve the sensitivity limits and dynamic range 
of this technique. This simple, quantitative and low cost method may be suitable for 
clinical application with further optimization. 
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CHAPTER IV 
 
KINETICS OF MOLECULAR RECOGNITION MEDIATED 
NANOPARTICLE SELF-ASSEMBLY 
 
Summary 
 Nanoscale quantum dot-antibody conjugates have been shown to self-assemble 
to form micron-scale aggregates in the presence of specific proteomic antigen. The self-
assembly process exhibits sigmoidal kinetics, suggesting that nucleation limits aggregation. 
Self-assembly kinetics in this study are characterized by flow cytometric analysis of the 
aggregation reaction over time. A range of physiologically relevant concentrations of the 
protein angiopoietin-2, a candidate cancer biomarker, are incubated with quantum dots 
conjugated with a polyclonal mixture of anti-angiopoietin-2 antibodies. Antigen 
concentration modulates the slopes and inflection times of the sigmoidal kinetics curves. 
An understanding of self-assembly kinetics in this system may lead to improvements in 
sensitivity and specificity of this novel proteomic biomarker detection technique and 
improve the screening, diagnostics, and therapy response monitoring for cancers and 
other diseases. This approach to studying the kinetics of nanoparticle self-assembly may 
also provide a valuable tool for understanding the fundamental characteristics of 
nanoscale particle aggregation. 
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Introduction 
 Directed self-assembly of nanostructures into microstructures through 
intermolecular interactions is an important phenomenon in many biological systems. 
Assembly of virus coat proteins into capsids[1], of microtubulin into microtubules[2], and 
of collagen[3] and fibrinogen into their respective fibrils are just a few examples where 
self-assembly plays a critical role in biological processes. Programmed self assembly using 
biomolecular interactions as a route to synthesis of novel nanostructured materials has 
also been an area of active investigation in the recent past[4, 5]. Techniques aimed at 
molecular diagnostics have also been demonstrated using nanoparticle self assembly 
mediated by molecular interactions, including polynucleotide interactions[6] and 
antibody-antigen interactions[7]. 
 In a recent publication[8], we demonstrated a novel technique for sub-picomolar 
quantitative detection of proteomic antigens using single step fluid phase incubation. In 
this technique, quantum dots (QD) conjugated with polyclonal antibodies (Ab) through 
the streptavidin-biotin interaction[9] are incubated with specific antigens in a 
physiological buffer. The molecular recognition between the antibodies and antigens 
causes aggregation of the nanoscale conjugates and proteins, resulting in the formation of 
microscale structures. These larger structures can be easily distinguished from the 
individual components based on differences in light scattering properties and by other 
analytical techniques. By sequentially characterizing very small volumes of the reaction 
mixture, such as via flow cytometry, the microscale aggregates can be quantified. At 
equilibrium, the antigen concentration and the fraction of events that are classified as 
aggregates are correlated through a log-linear relationship. Using multiple quantum dot 
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populations with distinct fluorescence emissions, multiplexed detection of two antigens is 
also feasible (unpublished data) and can, presumably, be extended through the use of 
alternately biofunctionalized QD with additional fluorescence emission characteristics.  
 In this short communication, we describe the kinetics of QD-Ab aggregation 
mediated by angiopoietin-2. The kinetics of self assembly of bio-macromolecules has 
been studied for many systems, including virus capsid assembly[1, 10], microtubule 
formation[2, 11, 12], fibril assembly[3] and other protein aggregation phenomena[13-16]. 
Theoretical[17-22] and computational[23-25] studies on these systems illuminate the 
mechanisms that drive the self-assembly processes. Previous work as also examined 
factors that influence the kinetics, such as the concentration of various moieties, agitation 
and presence of agents that promote or inhibit intermolecular interaction. These factors 
may be utilized for promotion or inhibition of aggregation [1, 14, 26, 27]. Understanding 
the kinetics of the present system may improve the specificity and sensitivity of the 
proposed diagnostic method. Similar studies yielded improvements to the conventional 
surface based enzyme linked immunosorbent assay (ELISA), and informed the 
development of the kinetic ELISA method[28]. While the current study explores the 
kinetics of highly specific molecular interaction mediated self-assembly, nanoscale 
material aggregation is important in a wide variety of applications. Controlled aggregation 
and/or prevention of non-specific aggregation are important considerations for various 
technologies that use nanomaterials, regardless of the presence or absence of molecular 
recognition. The techniques developed in this study may provide a novel method of 
quantitatively characterizing important aspects of nanoscale phenomena. 
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Experimental 
 
Materials 
 Streptavidin-coated quantum dots with 705 nm fluorescence emission (QD705, 
#Q10161MP) were purchased from Invitrogen (Carlsbad, CA) and used as received. 
Biotin conjugated anti-angiopoietin-2 polyclonal antibody (aA2, #BAF623), and 
recombinant human angiopoietin-2 (ang2, #623-AN) were purchased from R&D 
Systems (Minneapolis, MN), reconstituted in Tris-buffered saline (TBS) containing 0.1% 
bovine serum albumin (BSA) and stored at -20oC. Appropriate dilutions of all antibodies 
and antigens were prepared in phosphate buffered saline (PBS) with 0.1% BSA 
immediately prior to use. Deionized water with 18 MΩ.cm-1resistance was used for 
preparing buffers. All buffers were filtered through 0.2 μm filters. All other reagents 
were ACS reagent grade. Flow cytometric measurements were carried out with an 
unmodified Beckton Dickinson (BD) FACSCalibur, and the associated software. 
 
Quantum Dot – Antibody Conjugation 
 Quantum dot-streptavidin conjugates (QD) and biotinylated anti-angiopoietin-2 
polyclonal antibody (aA2) were mixed in PBS-BSA at QD:antibody molar ratio of 1:3 and 
1nM QD concentration. The conjugate was incubated for 30 minutes at room 
temperature and then used as synthesized. The stoichiometry in this protocol has been 
previously optimized to obviate the need to separate un-reacted antibodies from the 
QD-Ab conjugates[8]. The QD-aA2 conjugate solution and the ang2 or control solution 
at the appropriate dilutions and volumes were added to PBS-BSA for a final volume of 
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500 μL. BSA, similar to ang-2 in terms of molecular weight, was used as a negative 
control for Ang2.  
 
Agglomeration Kinetics Measurement Protocol 
 The reaction mixtures were incubated at room temperature and analyzed by flow 
cytometry at five minute intervals from t=5 minutes to t=90 minutes, as well as 
immediately after sample preparation, nominally t=1 minute. Thus, each experiment 
consisted of nineteen different samples, one for each time point. The influence of ang2 
concentration on aggregation kinetics was characterized by carrying out the aggregation 
reaction with 1 pM, 10 pM, and 100 pM ang2. Control measurements were made at the 
same time points on samples identical except for the presence of ang2. To compensate 
for the effect of the variability in the QD-aA2 dilution on the fraction of agglomerates 
observed, only the datasets with base QD-aA2 count within 2000+/-200 were utilized 
for analysis. Three such datasets for each antigen concentration comprised the analyzed 
data set.  
 The size, fluorescence and number of the aggregates in the incubated samples 
were characterized by flow cytometry. The basic flow cytometric protocol followed was 
similar to the one used in our previous publication[8]. Briefly, signal amplification 
parameters for the flow cytometer parameters forward light scatter (FSC) and side light 
scatter (SSC) detectors and fluorescence detector with 650nm long pass filters (FL3) 
were optimized for characterizing small particles. The FSC and SSC detector 
performance was calibrated by using 0.2, 0.5, 1, 2 and 2.8 μm latex calibration particles. 
In Figure 1, the regions indicated by R1, R2, R3, R4 and R7 correspond to the 0.2, 0.5, 1, 
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2 and 2.8 μm latex calibration particles respectively. The data was acquired at low flow 
rate (12 +/- 3 μL/min) for one minute. The FL3 channel was used as the event trigger 
consistent with the fluorescence emission characteristics of the 705 nm QDs used in this 
study. The fraction of aggregates was defined as the event fraction appearing in the upper 
right quadrant (UR) of the FSC vs. SSC plot. FSC greater than 10 a.u. corresponds to a 
nominal size greater than approximately 0.5 μm, as well as the observed differentiation 
of the individual QD-Ab conjugates from the large aggregates inherent in the 
agglomeration process and the measurement protocol[8]. Analysis of the datasets was 
carried out using the SigmaPlot 9.01 and SigmaStat 3.1 software.  
 
Results and Discussion 
 The kinetics of ang2 mediated QD-aA2 aggregation exhibits a sigmoidal behavior, 
with three distinct phases. The initial rate of aggregate formation is slow, most evident 
from the kinetics for aggregation triggered by the addition of 1 pM ang2 (Figure 2). The 
second phase characterized by rapid, self-assembled aggregation. The final phase is the 
reduction of aggregation rate with asymptotic approach to the equilibrium aggregate 
fraction. Similar sigmoidal kinetics are observed in many intermolecular interaction based 
self-assembly processes[27, 29] as well for nanoparticle synthesis [30] and polymer 
synthesis [29, 31]. Sigmoidal kinetics indicate a thermodynamically unfavorable 
intermediate in the reaction pathway. The key stages in the aggregation reaction are 
depicted schematically in Figure 3 where panel 1 represents the QD-Ab conjugates 
mixed with antigen molecules. Antibody-antigen recognition creates single  
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Figure 1: Time dependent change in flow cytometric data. Aggregation kinetics were 
characterized by flow cytometric analysis of ang2 mediated QD-aA2 aggregation at 
specific time points. Aggregates are quantified as a fraction of total events. The panels a, 
b and c show the raw flow cytometric data depicting increasing aggregate formation with 
time. This data was acquired for the samples with 10 pM QD-aA2 and 10 pM ang2 at 5, 
30 and 45 minutes in panels a, b and c, respectively. Each dot represents one particle or 
‘event’ detected. Forward light scatter (FSC-H) and side light scatter (SSC-H) intensities 
are positively correlated with the size and complexity of the particles. Optimization of 
the detection parameters enables the resolution of micron scale aggregates (red dots, 
upper right quadrant) from the individual QD-aA2 conjugates and small aggregates (black 
dots, bottom left quadrant). The ovals labeled R1, R2, R3, R4 and R7 indicate 0.2, 0.5, 1, 
2 and 2.8 μm calibration particles respectively. 
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Figure 2: Agglomeration kinetics for a range of angiopoietin-2 concentrations. The QD-
aA2:ang2 system exhibits a sigmoidal self-assembly kinetics. The parameters of 
aggregation kinetics in this system are affected by ang2 concentration, as detailed in 
Table 1. With increasing ang2 concentration, the aggregation rate increases, and time to 
inflection point (t0) and time to reach steady state aggregate fraction decreases. The 
difference between the slopes, including at t0 and at t=5 minutes for the three sigmoid 
curves suggest the possibility of antigen detection and quantification based on rate of 
increase in aggregate percent, rather than based on the equilibrium aggregate 
concentration as described previously[8]. This ability may also be beneficial for detection 
of molecular biomarkers in complex physiological media, where non-specific 
intermolecular interactions may have significant effect on the aggregate fraction, 
especially over long incubation periods. Each data point in the graph represents the mean 
and standard deviation of data from three different experiments. 
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QD-Ab:antigen complexes, which interact with each other, free QD-Ab conjugates and 
additional free antigen molecules. This is phase i of interactions which leads to the 
gradual formation of small complexes that act as nuclei for microscale aggregates. 
(Figure 3, panel 2). During the formation of multi-particle aggregates by molecular 
recognition, aggregation is favored by the decrease in free energy of the interacting 
particles, but the entropic cost associated with increased particle organization hinders 
nucleus formation[32]. Consequently, the probability of formation of micron scale 
aggregates as well as the aggregation rate are initially low. Once the nuclei have reached 
the critical size, the presence of multiple binding sites on the nuclei results in rapid 
growth of the aggregate[33]. This corresponds to phase ii, exhibiting rapid growth in the 
aggregate fraction. The transition from critical nucleus to large aggregates may occur 
rapidly. Flow cytometric characterization and dynamic light scattering data published 
previously[8], show only two particle populations – the individual, unaggregated QD-
aA2:ang2 conjugates and the micron scale aggregates. While the fraction of micron-scale 
aggregates changes over time, an intermediate population is not apparent in these data. 
The lack of detectable concentrations of intermediate is consistent with the data 
published in the literature for other aggregation systems cited previously. Finally, as the 
individual components are depleted (Figure 3, panel 3), the aggregation rate slows and 
the system reaches a stable steady state. 
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 Aggregation kinetics observed in the QD-aA2:ang2 system may be described by a 
three parameter, sigmoidal curve of the form 
)t-t(-
max
0
e-1
a a
τ
=     (Equation 1) 
 In Equation 1, a and t are the variables representing aggregate fraction and time, 
respectively. The constants for the sigmoids are amax, t0 and τ, where amax is the 
equilibrium value for a, t0 is the time point of inflection, and τ is a time constant. These 
parameters are modulated by the ang2 concentration in contact with the 
biofunctionalized QDs (Table 1). The amax values obtained from the sigmoidal curves fit 
to the 1 pM, 10 pM, and 100 pM ang2 datasets are statistically equivalent to the steady 
state aggregate fraction observed previously[8] for the respective ang2 concentrations. t0, 
which describes the inflection point for the sigmoidal curve, decreases with increasing 
ang2 concentration. Nucleation-limited aggregation processes, such as the self-assembly 
described here, accelerate in response to increased concentration of the bridging agent. 
This behavior, consistently observed in other systems and predicted in many model 
representations is confirmed in the present work. Increased ang2 concentration results in 
more rapid achievement of micron sized aggregates from nanoscale QDs, consistent with 
an increased rate of interactions between the QD-aA2 conjugates and the free ang2 
molecules in solution. Thus, increasing ang2 concentration causes earlier achievement of 
a significant nucleation subpopulation and more rapid transition to the aggregate growth 
phase. The effect of increasing ang2 concentration on aggregation rate is also evident in 
the difference in slopes of the aggregation curves. Antigen concentration modulates the 
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rate of aggregate formation at the early time points during the low aggregation rate 
phase as well as at the inflection point (Table 1). The different slopes observed for 
different ang2 concentration indicate that an unknown concentration of the target 
antigen may be estimated from the rate of increase in aggregate count at incubation 
times far shorter than those required to achieve steady state. The optimal time point for 
discriminating among antigen concentrations may be determined through comparative 
analysis of aggregation profiles. The time constant τ also decreases with increasing 
antigen concentration and corresponds with the higher rate of aggregation during phase 
two following nucleation. The ang2 concentration is correlated with the sigmoid 
coefficients amax, t0 and t, and the slopes at t=0 minutes and t=t0, with log linear 
functions with correlation coefficients 0.96, 0.98, 0.99, 0.95 and 0.99 respectively. These 
correlation coefficient values further support the feasibility of quantitatively detecting the 
biomarker concentration from one or more of the aggregation kinetics parameters. The 
control samples in the absence of ang2, do not exhibit time dependent aggregation 
behavior (Figure 2), further suggesting the potential to use kinetic assessments to detect 
specific antigens in the presence of other proteins. 
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Figure 3: Schematic depiction of nucleation limited agglomeration process. The 
sigmoidal kinetics observed for QD-aA2:ang2 self assembly suggests a nucleation limited 
process, which is schematically depicted here. i - The entropic cost of particle 
aggregation may outweigh the reduction in free energy, resulting in slow nucleation. ii - 
The presence of multiple binding sites on nuclei of critical size leads to rapid growth of 
aggregates. iii - The depletion in available free ang2 causes the asymptotic approach to 
equilibrium aggregate fraction. 
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Table 1: Modulation of aggregation kinetics parameters by angiopoietin-2 concentration. 
 
Angiopoietin2 
concentration 
(picomolar) 
amax 
(percent) 
t0 
(minutes) 
τ 
(minutes) 
slope, t=5 min 
(percent/minute) 
slope, t=t0 
(percent/minute) 
1 23.98 
+/- 0.35 
31.41 
+/- 0.38 
9.27 
+/- 0.76 
0.13 
+/- 0.02 
0.65 
+/- 0.05 
10 43.51 
+/- 0.35 
19.18 
+/- 0.84 
7.12 
+/- 0.16 
0.65 
+/- 0.05 
1.52 
+/- 0.05 
100 53.57 
+/- 0.30 
11.35 
+/- 0.53 
4.96 
+/- 0.21 
1.83 
+/- 0.09 
2.68 
+/- 0.11 
 
Table 1: Angiopoietin-2 concentration has quantifiable effects on QD-aA2 aggregation 
kinetics. The sigmoid curves fit to the aggregation data are described by three constants 
amax, t0 and τ. The equilibrium aggregate percentage, amax, increases with increasing ang2 
concentration, in agreement with previously published data[8]. The inflection time t0, and 
time constant τ both decrease with increasing ang2 concentration, indicating faster 
nucleation and growth of aggregates as a result of higher ang2 concentration. The rates 
of aggregation, represented by slopes of the sigmoidal curves are also a function of ang2 
concentration, including at t=5 minutes, and at t=t0. The concentration dependent 
aggregation rate may enable rapid detection and quantification of target antigens, as well 
as resolution of specific and no-specific intermolecular interaction. The values represent 
mean sigmoid coefficients and slopes obtained by fitting a three parameter sigmoid 
function to three datasets individually, and the respective standard deviations. The slopes 
at t=5 minutes and t=t0 were obtained by fitting a linear function to eight sigmoid curve 
data points centered on the corresponding time points, as generated by Sigmaplot. 
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Conclusions 
 The quantifiable and reproducible self-assembly in the QD-aA2:ang2 system 
exhibits a sigmoidal kinetic behavior, comparable to that observed in other self-assembly 
processes based intermolecular interaction. The kinetics of aggregation suggest that the 
rate of aggregation and the equilibrium extent of aggregation are sensitive to the antigen  
concentration. Further experimental and theoretical research will be used to 
characterize the kinetics of multiplexed antigen detection and QD-Ab aggregation in 
complex biological samples, but is not a part of this short communication. Due to its 
unique characteristics, this multifunctional nano-conjugate based analyte detection 
technique may provide a novel, simple, and rapid mechanism for detecting molecular 
biomarker from physiological samples. An understanding of the aggregation kinetics and 
mechanisms will be particularly important in developing practical implementations of this 
technology, especially for complex samples containing non specific antigens with weak 
intermolecular interactions that may support weak QD-Ab aggregation. Nanoscale 
particle aggregation in solutions is a fundamental phenomenon that affects various 
technologies that include nanomaterials. The approach demonstrated here for 
characterizing nanoparticle aggregation kinetics may be applicable for improving the 
experimental and theoretical understanding of these nanoparticle interaction mechanisms. 
Such new fundamental knowledge will presumably be important for fields other than 
directed self-assembly and molecular diagnostics applications of the present work. 
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CHAPTER V 
 
CONCLUSIONS 
 
Summary of Research 
 The dissertation explores a novel molecular diagnostic system based on molecular 
recognition mediated self-assembly of biofunctionalized nanoparticles. The three Specific 
Aims detailed in Chapter 1 were explored as described in Chapters II, III, and IV. 
Chapter II has been published in Langmuir[1], Chapter III is being revised for 
Nanomedicine: Nanotechnology, Biology, and Medicine (Elsevier)[2] and Chapter IV is 
under review in Nano Research (Springer)[3]. These chapters describe a new system of 
materials and methods that are aimed towards clinical development of a new technology 
for enhancing early diagnosis and therapy monitoring of cancers by monitoring soluble 
proteomic biomarkers. Furthermore, the novel nanoparticle self-assembly 
characterization protocol developed here may find broad applications in materials 
science. 
 In Chapter II we demonstrated the basic functionality of an in vitro system for 
detecting soluble proteomic biomarkers by characterizing self-assembled agglomerates of 
biofunctionalized nanoparticles. Quantum dots functionalized with polyclonal antibodies 
were shown to self-assemble into micron scale agglomerates in the presence of the 
specific antigens – angiopoietin-2 and mouse IgG, but not the non-specific control antigen 
– human IgG and bovine serum albumin. These agglomerates were characterized by 
multiple analytical methods, including dynamic light scattering, electrical sensing zone 
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method, and flow cytometry. While dynamic light scattering and electrical sensing zone 
methods were successfully used for demonstrating antigen mediated nanoparticle self 
assembly, the data was semi-quantitative, especially for the physiologically relevant 
picomolar and sub-picomolar concentrations.  
 The protocol developed for flow cytometric analysis of the reaction mixture 
allowed quantitative measurement of the number of agglomerates per unit volume and 
correlation of the agglomerate fraction to the antigen concentration. Since molecular 
recognition mediated self assembly is a two component process similar to agglutination, 
detection of low antigen concentrations was achieved by using low concentrations of the 
biofunctionalized nanoparticles. Using 10 pM QD-Ab conjugates, quantitative detection 
with a sensitivity limit of 500 pM was achieved by flow cytometry. The correlation 
between the antigen concentration and agglomerate fraction was log linear, with a 
correlation coefficient above 0.9 for both the antigens. The quantitative and reproducible 
measurement of antigen concentrations indicates the suitability of this technique for 
biomarker based clinical diagnostics. Furthermore, using two different concentrations (10 
pM and 100 pM) of the QD-Ab conjugates, a large dynamic range of detection was 
achieved for both the antigens – from 500 pM to 50 nM. 
 The fluorescence of the nanoparticle agglomerates was found to be comparable 
to the individual nanoparticles. The observed size of the agglomerates indicated that the 
agglomerates contained on the order of a thousand individual quantum dots. Based on 
this estimate, it was originally hypothesized that the fluorescence emission of the 
agglomerates will be an order of magnitude or more intense compared to the individual 
nanoparticles. The discrepancy suggested that either most of the quantum dots in the 
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agglomerates were not being completely excited by the excitation laser, or that the 
fluorescence emissions of most of the quantum dots were not reaching the fluorescence 
detector. To investigate the discrepancy between the observed and expected 
fluorescence of the agglomerates, the bulk fluorescence of the reaction mixture was 
characterized. These measurements demonstrated a marked decrease in the bulk 
fluorescence with time, especially for high concentrations of the antigen, but not for the 
non-specific control, in agreement with the two hypotheses. This observation also 
prompted an alternate configuration for the microfluidic device design. 
 Current literature evidence strongly suggests that the clinical power of the 
biomarker based cancer diagnostics approach is enhanced significantly when biomarker 
panels – consisting of multiple biomarkers – are quantitatively detected. The availability 
of multiple fluorescence detection channels on the flow cytometer enabled the detection 
of multiple proteomic antigens by this method. Multiplexed, quantitative detection of 
angiopoietin-2 and vascular endothelial growth factor A was achieved by optimizing the 
flow cytometric characterization protocol to minimize the effect of cross channel 
fluorescence detection and non-specific antibody-antigen reactions. This is described in 
Chapter III. The nanoparticle agglomerates were quantified in two different data-spaces – 
580 nm fluorescence vs. forward scatter intensity and 650 nm long pass fluorescence vs. 
forward scatter intensity. Each of the fluorescence intensity channels was used to trigger 
particle acquisition and characterization in two separate measurements of each sample. 
Agglomerates that exhibited cross fluorescent emissions exhibited high fluorescence in 
the data space with the trigger wavelength, but minimal fluorescence in the data space 
with non-trigger wavelength. Hence, the data spaces were gated to discard the events in 
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the low fluorescent intensity bins. This resulted in reproducible quantitative detection of 
the antigens, in the physiologically relevant concentration range of 1-100 pM. To test the 
reproducibility of the data, t-tests were carried out to compare the data sets in the 
multiplexed detection experiments with varying concentration of the two antigens, as 
well as the earlier dataset from non-multiplexed detection. The t-values obtained from 
these tests revealed that the correlation between antigen concentration and agglomerate 
fraction was statistically equivalent. The optimized detection protocol also enabled non-
multiplexed detection of antigens with increased sensitivity, reducing the sensitivity limit 
for both angiopoietin-2 and VEGF to 50 fM. 
  One of the key hurdles in detecting low concentration biomarkers in 
physiological samples is the presence of large quantities of carrier proteins and antibodies 
in the serum or plasma, which may react non-specifically with the antibodies on the 
biofunctionalized nanoparticles, as well as cause nanoparticle agglomeration through 
other non-specific intermolecular interactions. Preliminary investigation revealed this to 
be the case for the system under investigation, necessitating significant improvements in 
materials and methods for sensitive and quantitative detection of biomarkers from 
complex physiological samples. While a complete solution to this problem was deemed 
outside the immediate practical scope of this research, one of the key improvements in 
the method of characterizing the agglomerates was developed. Chapter IV describes the 
kinetics of nanoparticle agglomeration in the present system. Antibody-antigen reaction 
kinetics, similar to those utilized in kinetic ELISA, were characterized via flow cytometry. 
The kinetics of nanoparticle agglomeration in the presence of a range of angiopoietin-2 
concentrations was characterized from multiple time points up to ninety minutes. The 
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agglomerate fraction and time exhibited a sigmoidal correlation curve, which could be 
described by a three parameter sigmoidal equation. The parameters of the individual 
curves, as well as slopes at distinct time points were modulated by the antigen 
concentration, indicating the feasibility of quantitative detection of antigens from 
parameters other than the steady state agglomeration fraction. 
 
Future Work 
 The next steps in this research can be broadly demarcated into two 
interdependent goals. The first is development of this research into a viable diagnostic 
platform for biomarker panel based cancer diagnosis and monitoring. Ideally, such a 
technology will be able to detect multiple biomarkers simultaneously from whole or 
minimally processed blood, in a compact automated instrument. Such an implementation, 
which may reduce the cost and increase ease of use and robustness of the diagnostic, 
would significantly enhance the value of molecular diagnostics for the end user.  
 The second goal is a more detailed understanding of the effect of the multiple 
materials and methods on characteristics of the self-assembled agglomerates. The 
sensitivity, specificity, quantitativness, kinetics, and dynamic range of biomarker detection 
is modulated by various parameters, including antibody-antigen interaction affinity, QD-
antibody stoichiometry, size and surface chemistry of QD-Ab conjugates, fluid mixing 
parameters and presence of competitive and non-specific antigens.  
 It is anticipated that the specific capabilities of the microfluidic device will inform 
the design of experiments to elucidate the effect of the materials and methods on the 
diagnostic capability. Equally, the effect of materials and methods on optimizing the 
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protein detection capabilities will likely inform the configuration of the diagnostic 
platform. Some of the possible experimental and computational approaches for achieving 
these goals are described below.  
 
Effect of antibody-antigen interaction affinity on agglomerate characteristics 
 The interaction affinity between the polyclonal antibodies and the antigens is 
expected to be a major factor affecting the kinetics and steady state characteristics of 
agglomeration. While the work presented in this thesis exhibits the differences in 
correlation between antigen concentration and steady state agglomeration for several 
antibody antigen pairs, controlled experiments elucidating the effect of binding affinity on 
agglomeration characteristics may prove valuable for optimizing the QD-Ab conjugates 
for sensitivity, dynamic range and quantitativeness. 
 Such an experiment may be carried out by examining the agglomeration behavior 
of two antibody-antigen pairs where the antigens have similar molecular weight, and the 
interaction affinity is known. Alternatively, agglomeration mediated by a single antigen 
may be characterized with two different polyclonal antibody mixtures with known 
binding affinity values. In these experiments, the binding affinity values may be 
characterized by conventional immunochemistry methods if they are not available from 
the vendors. From the point of view of experimental simplicity, it would be preferable to 
characterize the agglomeration behavior in this and other experiments on a microfluidic 
platform, but the established flow-cytometry based protocol is an acceptable alternative. 
Development of a computational model of the agglomeration process will provide an 
additional way to rapidly examine the effect of interaction affinity on agglomeration. 
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 Effect of QD-Ab stoichiometry and size on agglomerate characteristics 
 The number of antibodies per QD-Ab conjugate, as well as the size of the QD 
would significantly affect the agglomeration geometry, and hence, protein detection 
parameters. Experiments with alternative QD-Ab stoichometries would inform the 
optimization of QD-Ab conjugates for protein detection. The careful control of QD-Ab 
stoichiometry will also involve purification of the conjugate for removal of unbound 
antibodies. If impact free antibody removal will inform the necessity for this extra step in 
clinical implementation. The effect of QD core size on the agglomeration behavior can 
be examined by characterizing the agglomeration behavior of an antibody-antigen pair, 
where the antibodies are conjugated with different QDs. These factors too can be 
investigated in a computational model of the agglomeration process along with physical 
experiments. 
 
Optimization of materials and methods for complex samples 
 For proteomic profiling applications, whole blood is commonly processed to 
remove the most prevalent proteins, which include hemoglobin, albumin, complement 
proteins, immunoglobulins, transferrin, and fibrinogen. These proteins are present in 
concentrations many orders of magnitude larger than the target biomarkers and cause 
non-specific aggregation. The removal of these components by conventional proteomics 
methods, such as separation columns may significantly improve the performance of the 
biomarker detection method. 
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 Another approach that may significantly reduce non-specific agglomeration is 
modification of the nanoparticles. It is well known that poly-(ethylene glycol) surface 
modified nanoparticles have significantly reduced non-specific adhesion to biological 
surfaces. A similar approach my also help reduce non-specific self-assembly of 
nanoparticles for diagnostics. Surface modification of quantum dots may also necessitate 
the development of a protocol for chemically conjugating antibodies to the nanoparticles, 
rather than streptavidin-biotin based conjugation currently used. 
 
Development of microfluidic device 
 While the characterization of nanoparticle agglomerates is easily possible with, 
conventional flow cytometers, these instruments are generally not optimized for 
accurate characterization of small particles. Furthermore, the optical set up in flow 
cytometers may not be optimal for characterization of these assemblies, as discussed 
before. A microfluidic device may overcome both of these challenges, and is currently in 
development. 
 
Examination of other intermolecular recognition interactions: 
 It is likely that nanoparticle agglomeration may be achieved from other 
intermolecular interactions such as for polynucleotides, DNA-Aptamer, and receptor-
ligands, interaction. Modifying the present system to examine these interactions would 
determine the feasibility of detecting non-protein biomarkers with this diagnostic 
platform. 
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Risks and benefits of further investment 
 The work presented here demonstrates that nanoparticle agglomeration based 
protein detection method works for protein detection with sensitivity comparable to 
ELISA and possibility of reduced cost and increased ease of use. However, significant 
improvements are required before it may be considered a viable technology for clinical 
diagnostics applications. These improvements may or may not be possible. Furthermore, 
a large number of molecular diagnostics technologies are currently under development, 
and the competitiveness of this technology, even with significant improvements, is not 
assured. 
 If the technology is implemented with competitive performance, the simple, low 
cost, portable implementation would likely ensure widespread clinical adoption for 
molecular diagnostics of a large variety of diseases. Furthermore, the technology also has 
the potential for use for outside the clinical setting investigation of nanomaterials 
agglomeration. 
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APPENDIX A 
 
PRELIMINARY CHARACTERIZATION OF MOLECULAR RECOGNITION 
MEDIATED NANOPARTICLE SELF ASSEMBLY 
 
 The initial experiments to ascertain the feasibility of this technique were carried 
out by non-invasive dynamic laser back scatter (DLS) in the Malvern Zetasizer Nano ZS 
(Malvern Instruments, Malvern, UK). QDot-525 Streptavidin conjugates (QD) (1μM, 
Invitrogen Corporation, Q10141MP), biotin conjugated goat anti-mouse immunoglobulin 
specific polyclonal antibody (GaM) (0.5 mg/mL, BD Pharmingen, 553999), Mouse IgG 
(Mus) (Polysciences, 23873) and Human IgG (Hum) (Polysciences, 23872) were used 
without further purification. Borate buffer (ACS boric acid/sodium tetraborate, 10 
mmol/L, pH 7.4, 0.2 μm filtered) was used for these experiments. 
 Quantum dot - antibody conjugation was verified by DLS particle size 
measurement. Particle size measurement of the individual particles shows (Figure 1.a) 
QD at 22 nm, Mus at 28 nm, and GaM at 9 nm and 28 nm. QD-GaM conjugates were 
prepared by adding GaM with QD:GaM molar ratio of 1:3, and incubating at room 
temperature for five minutes. The conjugation takes place due to biotin-streptavidin 
interaction. The particle size distribution after conjugation (Figure 1.b) indicates 
successful conjugation that QD reacts completely to produce a QD-GaM conjugate, with 
a diameter of 40 nm. It is also seen that some unreacted GaM persists, indicating that 
there are between two and three GaM per QD in the conjugate nanostructure. 
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 Immunorecognition mediated agglomeration was also verified by DLS 
measurements. 4μmol/L Mus - the positive antigen, was added to the QD-GaM solution. 
This mediated the appearance of a new peak beyond 1000 nm (Figure 1.c), indicating 
the formation of microscale agglomerates. Furthermore, the shift of the QD-GaM peak 
from 40 nm to 70 nm indicates formation of QD-GaM:Mus complexes that do not 
participate in microscale agglomerates. The addition of Hum – the nonspecific control 
antigen, does not mediate such agglomeration (Figure 1.d) which confirms the 
immunospecificity of the assay. The formation of large agglomerates in the presence of 
target antigen is a critical feature for successful application of the proposed approach, and 
is demonstrated here. 
 Correlation of QD-GaM-Mus agglomeration with Mus concentration was 
characterized by measuring particle size and count by electroresisitive meansurements 
(Beckman-Coulter Multisizer 3, 30 μm aperture). Particle size distribution above 800 nm 
diameter was assessed. Self-assembly of 2 pmol QD-GaM and 10 μL of antigen or 
negative control was carried out in 1 mL total volume of borate buffer for one hour at 
room temperature with continuous gentle mixing followed by dispersion in 9 mL Isoton 
II (Beckman Coulter, 8546719, 0.2 μm filtered).  Particle diameter distribution was 
measured from 0.8 to 8.0 μm in a 100 μL volume. 100 μg/mL Mus mediates a 115-fold 
increase in the number of particles between 0.8 to 8.0 μm in diameter relative to the 
addition of 100 μg/mL Hum, confirming the specificity of self-assembly (Figure 2).  The 
limit of detection for Mus in this non-optimized system appears to be approximately 1 
μg/mL, a concentration which produces the same number and volume of aggregates as 
100 μg/mL Hum or the QD-GaM background in the absence of antigen. The mean,  
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1.d 
 
 
 
Figure 1. Dynamic light scattering characterization. QD and GaM (1.a) conjugate via biotin-
streptavidin interaction.  Conjugate QD-GaM (1.b) has a mean size of around 45 nm. Excess 
GaM from the conjugation can also be seen. Specific antigen added to the QD-GaM conjugate 
causes agglomeration (1.c) producing a new particle population, while non-specific antigen does 
not cause this effect (1.d). 
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Figure 2 Electrical sensing zone characterization. Mus triggers the formation of microscale 
aggregates from nanoscale QD-GaM. The particle count and size distribution above 800 nm is a 
function of Mus concentration. 
 
 
 
 
 
 
 
 
 
 
 
 
 
103 
volume-weighted particle diameter measured by Coulter Counter was 2,780 nm or 
1,880 nm for QD-GaM treated with 1 μg/mL or 100 μg/mL Mus, respectively.  The 
equivalent number-weighted particle diameters were 1,050 nm or 990 nm, respectively. 
 Flow cytometric detection of QD-GaM-Mus agglomerates was also achieved.  
Flow cytometric detection was optimized in several ways, differing from conventional 
cellular flow experiments. Instead of forward scatter (FSC) or side scatter (SSC), 
fluorescence (FL) channels were found to be better event triggers, leading to higher 
particle count as well as reduced noise. The extinction coefficients of QDs increases with 
increasing emission wavelength. Accordingly, QDs with longer wavelength generate a 
higher particle count than QDs with shorter emission wavelength, at equal concentration. 
Hence for flow cytometric experiments, QD-705 streptavidin conjugate (QD) (1μM, 
Invitrogen Corporation, Q10161MP) was used.  Events were collected using 
fluorescence intensity in the FL3 channel (appropriate for QD705) as the primary event 
trigger (Becton-Dickinson FACSCalibur).  FL3 gain, SSC gain and FSC amplification were 
optimized in pilot studies to provide suitable dynamic range for capture of the relevant 
events.  
 QD-GaM interaction with antigen (1, 10 or 100 μg/mL Mus - Figure 3 b, c and d, 
respectively) or control (PBS buffer or 100 μg/mL Hum - Figure 3 a and e, respectively) 
was carried out in a standard flow cytometry tube (1 mL total volume) with incubation 
for one hour at room temperature. Based on flow cytometry of QD-GaM in the absence 
of any antigen, it was determined that most QD-GaM events had FSC values of less than 
10 arbitrary units (a.u.) at the amplification used. Hence, quad regions were established 
in the SSC vs. FSC representation to isolate, and identify through color gating (red for 
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Mus, blue for Hum), events with light scatter characteristics consistent with large particle 
diameter, based on forward scatter higher as a discriminating parameter.  
 This flow cytometric detection of self-assembled microscale aggregates formed 
from nanoscale conjugates and antigens confirms the particle size measurements by DLS 
(Figure 1) and electrical resistance (Figure 2), reinforcing the fundamental proof-of-
principle for the proposed approach. The flow cytometric data is also correlated with 
antigen concentration. FSC intensity histogram (Figure 4.a-d), as well as aggregates as a 
fraction of total events and mean diameter (Figure 4.e), are some of the parameters 
that reflect this correlation. FSC intensity histograms reflect the self-assembly of QD-
GaM-Mus aggregates modulated by [Mus]. Calibration particles (mean diameters 200, 
1000, 2000 and 2866 nm; corresponding to regions R1, R2, R3, and R4 respectively in 
Figure 3) were used to estimate the relationship between FSC intensity and event 
diameter[1]. The fraction of all events with forward scatter parameter greater than 10 is 
correlated with Mus concentration between 5 and 100 μg/ml, enabling antigen 
concentration estimation from measurable aggregate characteristics, at least in the model 
system tested. The diameter of QD-GaM-msIgG aggregate self-assembly decreases with 
increasing [Mus] from very large events (2,940 nm, FSC = 1187 a.u.) near the current 
[Mus] detection threshold (Figure 4.b, 1μg/ml Mus) to events centered near 1790 nm 
diameter (FSC = 345 a.u., Figure 4.c) and events centered near 760 nm diameter (FSC 
= 41 a.u., 100μg/ml, Figure 4.d) for the highest [Mus]. The QD-GaM-IgG FSC 
histogram mediated by the addition of nonspecific control antigen (100 μg/mL Hum, 
Figure 4.e) is visually different from that for the same concentration of Mus.   
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Figure 3  Flow cytometry: FSC-SSC dot plots. Flow cytometry reveals self-assembly of QD-
GaM-IgG aggregates modulated by antigen concentration (a, b, c, d : [Mus] of 0, 1, 10, 100 
μg/mL, respectively). 100 μg/mL of nonspecific control antigen (Hum) (e) mediates the self-
assembly of smaller and fewer aggregates than the same concentration of Mus. 
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Figure 4  Flow cytometry: FSC histograms. Comparative size distribution of QD-GaM-IgG 
aggregates modulated by antigen concentration (panels A through D reflect [Mus] of 0, 1, 10, 100 
μg/mL, respectively ).  100 μg/mL of nonspecific control antigen (Hum, e) mediates the self-
assembly of smaller and fewer aggregates than Mus (d). 
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Figure 5  Flow cytometry: fluorescence-FSC dot plots. QD-GaM fluorescence intensity is 
quenched by self-assembly into QD-GaM-IgG aggregates mediated by  antigen.  Events greater 
than approximately 490 nm in diameter are colored green.  The bottom subpopulation in panel B 
represents QD-GaM-Mus aggregates formed in response to 10 μg/mL Mus.  FL3 intensity does 
not increase in proportion with estimated event volume, evidence consistent with QD 
fluorescence quenching upon binding. 
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 Also, exposure to 100 μg/mL Hum resulted in significantly fewer FL3-positive 
events (2.71 x 103) than 100 μg/mL Mus (1.02 x 106), both in approximately 60 μL of 
detection volume. This confirms that gating strategies and statistics can be used to 
distinguish specific from nonspecific self-assembly. The reduced number of detectable 
events in flow cytometry for the Hum sample is consistent with the relative lack of 
aggregates greater than 700 nm diameter obtained by light scattering (Figure 1) and 
electric sizing (Figure 2).  
 Mus, but not Hum, mediates the formation of many self-assembled QD-GaM-IgG 
aggregates sufficiently large to trigger flow cytometric detection.  The use of absolute 
event counts may provide another sensitive index to distinguish antigen-mediated self-
assembly from nonspecific effects. Mean QD-GaM-Mus diameter may be used to 
characterize antigen mediated self-assembly, especially for low [Mus] where the 
population of aggregates is low and relatively insensitive to [Mus]. QD-GaM-Mus 
aggregate characteristics modulated by [Mus] suggest that antigen mediated self-assembly 
is a complex interaction in which the estimated event diameter decreases as the event 
fraction and [Mus] increases.  This behavior may be related to Mus:QD-GaM 
stoichiometry and mixing conditions, parameters that will be assessed by experimentally 
in this work. The use of absolute event counts may provide another sensitive index to 
distinguish antigen-mediated self-assembly from nonspecific effects.  Absolute counts and 
absolute volumes may be resolved in flow cytometry through the addition of microscale 
calibration particles of known concentration as the correlation measure. The threshold 
for Mus detection using FSC gated QD-GaM-Mus event counts in this non-optimized 
system appears to be 1 μg/ml or 6.6nM. The improvement of immunodetection by 
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optimizing reaction conditions, stoichiometry, and instrument parameters is one of the 
goals of specific aim I of the proposed research. 
 The fluorescence intensity of the aggregates is also significantly lower than 
expected from a linear increase in fluorescence of an agglomerate of multiple quantum 
dots. This can be seen (Figure 5.b) in the FL3 vs. FSC representation of the flow 
cytometric data as well as in the data bulk fluorescence intensity data (Chapter 2, Figure 
4). As an example, the QD-GaM-Mus aggregates at FSC intensity of 100 a.u. (1,085 nm 
diameter) have an FL3 intensity of approximately 1 a.u. and aggregates at FSC intensity of 
10,000 a.u. (6,940 nm diameter) have an FL3 intensity of approximately 10 a.u.  Thus, 
large events have more than 250-fold greater volume than small events, but only 10-fold 
the fluorescence intensity.  This behavior is consistent with other observations of QD 
fluorescence quenching upon surface modification [2, 3]; this response has been used as 
a biosensor [4, 5]. Other mechanisms, including optical screening, may contribute to this 
effect and will be assessed by spectrofluorometric assay during antigen-mediated self-
assembly as part of Specific Aim 1 of the proposed work.  
 A reduction in bulk fluorescence emission intensity at 585 nm mediated by the 
addition of 100 μg/mL Mus (but not 100 μg/mL Hum) suggests that QD quantum yield is 
quenched by antigen bridging (Chapter 2, Figure 4).  The observed reduction in overall 
solution fluorescence intensity is consistent with the reduction in QD-GaM-Mus 
fluorescence intensity measured by flow cytometry (Figure 5). Other measures of 
nanoparticle self-assembly described here (aggregate size, aggregate fluorescence 
intensity) have a greater sensitivity to antigen than the 10-100 μg/mL threshold apparent 
in this non-optimized system.  Fluorescence intensity measured in this method is the sum 
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of QD-GaM and QD-GaM-IgG aggregates.  For conditions in which the volume fraction 
of aggregates is small (approximately 0.001% in these studies (Figure 2)), fluorescence 
quenching due to aggregation must be detected on a relatively large background 
fluorescence intensity of unaggregated QD-GaM.  This disadvantage may be overcome 
by optimization of the [QD-GaM] and has been successfully demonstrated in other 
systems [5, 6].  
 Polychromatic agglomerates have also be detected and characterized. A mixture 
of two unique QD populations (QD585 and QD705) can self assemble though antigen 
binding to form polychromatic aggregates (Figure 6).  This evidence supports the 
spectral unmixing of QD aggregates to simultaneously characterize the presence of 
multiple antigens in a mixture by flow cytometry.  QD705-GaM (Figure 7.a) are strongly 
fluorescent in FL3, but not FL2.  QD585-GaM (Figure 7.b) are strongly fluorescent in FL2, 
but not FL3.  Equal proportions of QD705-GaM and QD585-GaM mixed with 100 μg/mL 
Mus, resulted in the self-assembly of aggregates with sizes indistinguishable from those 
composed of QD705 alone (compare Figure 6.c and Figure 3.d).  The polychromatic 
aggregates, simultaneously emitting significant fluorescence intensity in both FL2 and FL3 
(Figure 6.d), were composed of both QD cohorts.  
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Figure 6  Preliminary multicolor flow cytometry. QD705-GaM (a) and QD585-GaM (b) are mixed 
together in equal proportion and exposed to 100 μg/mL msIgG antigen.  The self-assembled 
aggregates are formed (c) from both QD cohorts, creating polychromatic events (d). 
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7.a 
Extinction Spectra of CdSe/ZnS Qdot Conjugates
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Emission Spectra of CdSe/ZnS Qdot Conjugates
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Figure 7  QDot absorption and excitation spectra. Excitation(a) and emission (b) spectra of 
CdSe/ZnS quantum dots. Data provided by Quantum Dot Corp.  
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